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ABSTRACT 
Melanoma is one of the most aggressive malignant tumours, due to its high 
metastatic potential and resistance to current treatment modalities. Patients with 
metastatic melanoma present poor prognosis, with an overall survival of 8 to 18 months 
and limited meaningful therapeutic strategies. Systemic treatment options for advanced 
melanoma include single-agent or combination chemotherapies. Paclitaxel is 
recommended as a first or second-line strategy for systemic therapy of metastatic 
melanoma, both in monotherapy and in combination with platinum compounds. 
However, paclitaxel as all other currently available treatment options are associated with 
limited efficacy and combinations increased toxicities without significantly improve 
survival rates. Therefore, alternative therapeutic strategies for metastatic melanoma are 
urgently needed. 
Several lines of evidence have hypothesized a role of adenosine in tumour 
development and growth. Studies suggest a contradictory role of adenosine in the viability 
of normal and cancer cells, ascribed to the stimulation of the four adenosine receptor 
subtypes, named A1, A2A, A2B, and A3, which couple to different signal transduction 
pathways and can be co-expressed in the same cell. 
The overall aim of this thesis was to study the role of adenosine/adenosine 
receptors in the complex interplay of proliferation, cell death mechanisms and metastatic 
progression of melanoma, and to provide clues for the development of new therapeutic 
strategies for metastatic melanoma. 
The expression of A1, A2A, A2B and A3 adenosine receptors, on human C32 and A375 
and mouse K1735-M2 melanoma cells, was shown. Activation of adenosine receptor 
subtypes A1, A2A, and A3 did not affect cell proliferation of A375 and K1735-M2 cells. 
However, proliferation of C32 cells was increased, after activation of A3 adenosine 
receptor, by micromolar concentrations of adenosine or nanomolar concentrations of the 
selective A3 agonist, Cl-IB-MECA. However, Cl-IB-MECA, at micromolar concentrations, 
caused marked cytotoxicity, through A3-independent mechanisms. 
Results indicate a major role for A3 adenosine receptors in C32 cell proliferation 
induced by inosine, through PLC-PKC-MEK1/2-ERK1/2 pathway activation. However, 
activation of the PI3K pathway, mediated by P2Y1 receptors, was also found to be involved. 
Inosine also enhanced proliferation of the A375 cell line and stimulated the metastatic 
processes evaluated in both cell lines (migration, adhesion, invasion and colony-
formation), through A3 adenosine receptor activation. These results suggest inosine as an 
aggressiveness agent for these human melanoma cell models. Furthermore, the observed 
inosine pro-angiogenic effect (microvessel sprouting) is A3-independent. 
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The combination of Cl-IB-MECA and paclitaxel was studied, emerging as a 
promising cytotoxic combination for metastatic melanoma, acting through the induction 
of multiple mechanisms of cell death (apoptosis with the involvement of mitotic 
catastrophe, and mTOR-dependent autophagy) and inhibition of the aforementioned 
metastatic processes, involved in melanoma progression. This new therapeutic strategy 
seems to be able to overcome melanoma chemotherapy multiresistance, through 
activation of alternative cell death mechanisms, and to stop, or delay, melanoma 
progression, potentially improving treatment and prognosis of patients with metastatic 
melanoma. 
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RESUMO 
O melanoma é um dos tumores malignos mais agressivos, devido ao seu elevado 
potencial metastático e resistência às modalidades de tratamento disponíveis. Doentes 
com melanoma metastático têm mau prognóstico, com uma sobrevida global de 8 a 18 
meses, e estratégias terapêuticas limitadas. Opções de tratamento sistémico para o 
melanoma avançado incluem monoterapias e combinações de agentes quimoterápicos. O 
paclitaxel é recomendado como agente de primeira ou segunda linha para a terapêutica 
sistémica do melanoma metastático, em monoterapia ou em combinação com compostos 
de platina. No entanto, o paclitaxel tal como todas as opções terapêuticas actualmente 
disponíveis estão associadas a baixa eficácia terapêutica e as combinações apresentam 
aumento de toxicidade sem melhorar significativamente as taxas de sobrevida. Por estas 
razões, são necessárias, urgentemente, estratégias terapêuticas alternativas para o 
melanoma metastático. 
Vários trabalhos sugerem que a adenosina desempenha um papel importante no 
desenvolvimento e crescimento tumorais. Este nucleósido foi descrito como afectando, de 
modo diferencial, a viabilidade das células normais e cancerosas, através da ativação dos 
quatro subtipos de recetores de adenosina, denominados A1, A2A , A2B e A3, que podem 
acoplar a vias de transdução de sinal diferentes e ser co-expressos numa mesma célula. 
O objetivo geral desta tese foi estudar o papel da adenosina e dos seus recetores na 
complexidade das interações entre a proliferação, os mecanismos de morte celular e a 
progressão metastática do melanoma, e encontrar indicações para o desenvolvimento de 
novas estratégias terapêuticas para o melanoma metastático. 
Foi mostrada a expressão dos recetores da adenosina A1, A2A, A2B e A3, em células 
C32 e A375 de melanoma humano e células K1735-M2 de melanoma de ratinho. A 
ativação dos subtipos dos receptores da adenosina A1, A2A e A3 não afetou a proliferação 
celular das células A375 e K1735-M2. No entanto, a proliferação das células C32 foi 
aumentada, após a activação do receptor A3 da adenosina, por concentrações 
micromolares de adenosina ou nanomolares do agonista selectivo A3, Cl-IB-MECA. No 
entanto, Cl-IB-MECA, em concentrações micromolares, causou citotoxicidade, através de 
mecanismos independentes da activação dos recetores A3. 
Os resultados indicam um papel importante para os recetores A3 da adenosina na 
proliferação das células C32, induzida pela inosina, através da ativação da via da PLC-
PKC-MEK1/2-ERK1/2. No entanto, a ativação da via da PI3K, mediada por recetores P2Y1, 
também está envolvida. A inosina promoveu ainda a proliferação das células A375 e 
estimulou os processos metastáticos avaliados em ambas as linhas celulares (migração, 
adesão, invasão e formação de colónias), através da ativação do recetor A3 da adenosina. 
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Estes resultados sugerem a inosina como um agente de agressividade nestes modelos 
celulares de melanoma humano. Além disso, o efeito pró-angiogénico estimulado pela 
inosina (formação de microvasos a partir de anéis de aorta de ratinho) é independente da 
activação dos receptores A3. 
Estudou-se a combinação terapêutica Cl-IB-MECA e paclitaxel, que se revelou uma 
combinação promissora para o tratamento do melanoma metastático, através da indução 
de múltiplos mecanismos de morte celular (apoptose com o envolvimento de catástrofe 
mitótica e autofagia dependente do mTOR) e inibição dos processos metastáticos acima 
mencionados e que estão envolvidos na progressão do melanoma. Esta nova estratégia 
terapêutica parece ser capaz de superar a resistência do melanoma à quimioterapia, 
através da ativação de mecanismos alternativos de morte celular, e de parar, ou atrasar, a 
progressão do melanoma, melhorando, potencialmente, o tratamento e prognóstico dos 
doentes com melanoma metastático. 
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A. LITERATURE REVIEW 
	 1. MELANOMA 
 
 Metastatic melanoma is considered one of the most aggressive malignant tumours, 
representing the deadliest form of skin cancer [1]. This serious disease, whose cells are 
derived from transformed epidermal melanocytes, has, currently, an alarming increase in 
incidence rates [2]. Although melanoma is less common than other types of skin cancer, 
the incidence of cutaneous melanoma is rising faster than any other solid tumour [3], 
accounting for a global incidence of about 160 thousands new cases each year [4]. This 
increased incidence may be a consequence of more people chronically exposed to 
natural/artificial UV radiation and/or higher detection rates associated with enhanced 
public awareness [5]. In Portugal, melanoma incidence is estimated to be 8/100,000 
persons per year, with an overall increasing incidence of 6-7% per year [6]. 
 
 
	 1.1 Melanocytes and skin 
 
 Melanocytes are pigment-producing cells of the skin in humans and other 
vertebrates [7]. They are originated from embryonic neural crest cells (melanoblasts) that 
gradually become more differentiated during development [8]. The life cycle of 
melanocytes consists in i) migration and proliferation of melanoblasts, ii) differentiation 
into melanocytes, iii) maturation of melanocytes (melanin production in melanosomes, 
dendritic morphology), iv) transport of melanosomes to keratinocytes and v) eventual cell 
death [9]. Although pigment cells are found throughout the skin, they are also present in 
the hair, eye, inner ear, central nervous system, mucosal membranes, heart, and muscle 
[10]. It is well accepted that melanocytes establish dynamic interactions with the skin 
microenvironment, in particular with keratinocytes (Figure 1) [9]. 
 Melanocytes are found in the basal layer of epidermis where they form the 
epidermal melanin units. These are defined as functional units composed of one 
melanocyte and approximately 36 associated keratinocytes [11]. It is accepted that each 
melanocyte, through its multiple dendrites, transports melanin-containing melanosomes 
to keratinocytes, although the precise transfer process is not completely understood [12]. 
Melanin, produced in melanocytes through the involvement of tyrosinase activity, absorbs 
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and scatters ultraviolet (UV) radiation, preventing DNA damage of keratinocytes and 
melanocytes [13]. 
 Complex signalling networks between keratinocytes, melanocytes, fibroblasts, and 
extracellular matrix (ECM) include not only the transfer of melanin to keratinocytes, but 
extensive cytokine, hormonal, and growth factor signalling, which maintains skin 
homeostasis [10,14]. 
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Figure 1. The human skin is constituted of two distinct layers, the epidermis and the dermis, which are 
separated by the basement membrane. Melanocytes, found in the epidermal basal layer, synthesize melanin in 
melanosomes, which are then transported into keratinocytes, through dendritic processes. Modified from [9]. 
 
 
	 1.2 Melanoma development 
 
 Currently, divergent hypothesis are proposed to explain melanoma development. 
In individuals with a tendency to develop large numbers of nevi, melanomas are initiated 
after modest solar radiation exposure, after which host factors drive further progression; 
on the contrary, in individuals with little or no tendency to develop nevi, chronic exposure 
to the sun seems crucial for melanoma development [10]. This could justify the different 
mutation patterns found in skin areas, chronically or non-chronically, exposed to solar 
radiation [15]. Nevertheless, approximately 75% of melanomas arise from normal skin in 
the absence of pre-existing nevi [16]. 
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 Endogenous risk factors like previous family history of melanoma, and multiple 
dysplastic or benign nevi, blond or red hair, and pale skin have revealed a strong 
association with melanoma development [1]. However, exogenous risk factors including 
long term sun exposure, photochemotherapy, and photographic chemicals exposure are 
also reported to favour the development of melanoma [17]. 
 Solar UV radiation has been linked to skin cancer, both in non-melanoma 
(transformed keratinocytes) and melanoma (transformed melanocytes) cancers [18]. Skin 
malignant changes promoted by UV solar radiation (i) cause DNA mutagenic effects; (ii) 
increase the production of growth factors by skin cellular constituents; (iii) reduce the 
cutaneous immune defences; and (iv) promote reactive oxygen species (ROS) formation 
[19]. 
 Although epidemiological studies have linked solar UV radiation to melanoma 
[20], the specific contribution of UVB and UVA radiation exposure in the risk of 
developing melanoma is controversial. UVB, the minor but the most damaging solar light 
component, causes direct DNA damage on cells of skin epidermal basal layer, since UVB 
wavelengths are within the DNA absorption spectrum [21]. UVA wavelengths (more 
abundant) penetrate into the epidermis and dermis of the skin, generating ROS that can 
damage cellular components, including DNA [22]. Nevertheless, evidence suggests that 
both UVA and UVB radiation act together to promote the development and progression of 
melanoma [23,24]. 
 Skin has endogenous defence systems that limit the potential damage caused by 
UV radiation, such as melanin, antioxidant enzymes, and DNA repair enzymes [21]. 
However, these endogenous photoprotective mechanisms are not always sufficient to 
neutralize the adverse effects caused by UV radiation. Thus, melanocytes that have 
accumulated abnormalities in their DNA may develop melanoma. The abnormalities can 
promote a malignant phenotype, which include cell proliferation and impaired apoptosis, 
stimulation of angiogenesis, escape from the immune system, tumour invasion, and finally 
metastasis [19]. 
 
 
	 1.3 Melanoma progression 
 
 Despite the origins for melanoma remain controversial, with melanoma 
development starting either from a nevus or directly from cutaneous melanocyte, 
melanomas generally undergo several stages of growth (Figure 2). 
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 Initially, cells proliferate in a radial-like fashion within the epidermis (radial 
growth phase). These lesions can then progress with cells breaking through the basement 
membrane and invading the dermis (vertical growth phase) [25]. At this stage, cells 
become autonomous, producing their own growth factors independently from 
keratinocytes, being able to invade blood and lympha [26,27]. These events first lead to 
local metastasis and eventually to distant metastasis [26]. However not all melanomas 
have these individual stages [28]. Both radial and vertical growth phases can develop 
directly from either single melanocytes or nevi, and both can progress directly to 
metastatic melanoma [29]. 
 Some melanomas retain physical characteristics of melanocytes, namely 
pigmentation, giving melanomas a highly pigmented phenotype, whereas others lose this 
ability and are amelanotic. Overall, melanomas present heterogeneity concerning cell 
morphology and pigmentation level [30]. 
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Figure 2. Different stages of human melanoma. Aberrant proliferation of normal melanocytes results in the 
formation of benign or dysplastic nevus. In the radial growth phase, melanoma exhibits the ability to grow 
intra-epidermally, followed by invasion of the dermis in the vertical growth phase, and culminating with 
metastasis. Note that not all melanomas arise from nevi, and progression can occur without going through all 
the stages depicted. Modified from [25,29,31]. 
 
 
 Malignancy hallmarks of cancers, including rapid and uncontrolled proliferation, 
invasion, and distant organs colonization, can be attributed, in part, to deregulation of 
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interactions between neoplastic cells and cellular microenvironment [32]. Following 
malignant transformation, melanoma cells become autonomous and no longer respond to 
keratinocytes trophic stimulation signals [27]. Development of melanoma metastasis 
starts with cell migration from the primary tumour, followed by re-adhesion and tissue 
invasion [33]. Proteolytic degradation of basement membrane and ECM represents a 
critical step for melanoma invasion and metastasis, since it displaces the surrounding 
matrix, which is required for cells to move into surrounding tissues [28]. In addition, 
anchorage-independent growth (colony formation) is also important for malignant cell 
transformation as this ability identifies tumours with metastatic potential [34]. As such, 
new colonies of melanoma cells dramatically increase the consumption of oxygen and 
nutrients, eventually leading to cell starvation and hypoxia on the tumour site [35]. These 
increasing demands induce the development of additional vasculature in order to increase 
blood supply, triggering angiogenesis [25]. 
 
 
	 1.3.1 Signalling pathways involved in melanoma progression 
 
 Disruption in crucial signalling pathways that regulate normal melanocyte function 
is strongly linked to melanoma development and progression [36,37]. Several signalling 
pathways were found to be constitutively activated in melanoma. Among them, the 
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)-AKT 
signalling pathways are activated in melanoma and appear to play major roles in cell 
proliferation, melanoma development and its progression [38]. Both were found to be 
constitutively activated in most melanomas [4,39]. Moreover, intrinsic resistance to 
apoptosis is also involved in the regulation of melanoma progression [40]. 
 
 
	 1.3.1.1 Mitogen-activated protein kinase pathway 
 
 Aberrant MAPK pathway [Ras–Raf–mitogen-activated protein kinase kinase 
(MEK)–extracellular signal-regulated kinase (ERK)] activation is being implicated in the 
regulation of cancer, namely cellular proliferation, differentiation, and survival [41]. 
Briefly, stimulation of Ras causes activation of Raf, which then phosphorilates MEK, 
leading to activation of ERK (Figure 3). 
 Activation of the MAPK pathway is a frequent and early event in melanoma 
development [42]. During the process of malignant transformation, melanocytes acquire 
the ability to secrete autocrine and paracrine growth factors [43]. Many of these factors 
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contribute to the increased ERK activity in melanoma through direct activation of the Ras-
Raf pathway [39]. Moreover, this activation may also occur via phospholipase C (PLC)-
protein kinase C (PKC) (Figure 3), since PKC can induce direct activation of Raf, triggering 
MEK1/2 cascade activation (reviewed in [44]). In addition, the ERK1/2 activation involved 
in cellular proliferation was also reported to be dependent of G protein-PKC-MEK1/2 
signalling [45]. 
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Figure 3. Schematic representation of the MAPK (Ras-Raf-MEK1/2-ERK1/2) signalling pathway in 
melanoma cells. An extracellular factor interacts with its receptor and induces activation of Ras which in turns 
phosphorilates Raf. Activated Raf then phosphorylates and activates MEK1/2 which phosphorylates and 
activates ERK1/2. Nevertheless, extracellular factors may also activate PLC-PKC (through a G protein-
mediated effect) which can also activate MEK1/2. Activated ERK1/2 has substrates in the cytosol but can also 
enter the nucleus and regulate gene expression. 
 
 
 Mutations of N-Ras or B-Raf, autocrine and paracrine growth factors, and 
adhesion receptor activation represent some of the multiple mechanisms through which 
Ras-Raf-MEK-ERK signalling pathway is activated in melanoma [39]. Extracellular 
signals generated through the interaction of ligand-receptor are transmitted to the interior 
of melanoma cells, activating downstream signalling cascades (Figure 3). Finally, ERK1/2 
either phosphorylates cytoplasmic targets or migrates to the nucleus, where it 
phosphorylates and activates several transcription factors, such as c-Fos or Elk-1 [46]. 
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 Evidence indicates that MEK1/2 inhibitors can block ERK activity of human 
melanoma cell lines, leading to melanoma cell cycle arrest [47]. Therefore, the MAPK 
pathway seems essential for cellular proliferation. 
 
 
	 1.3.1.2 Phosphatidylinositol-3-kinase pathway 
 
 Constitutive activation of the PI3K-AKT pathway can trigger a cascade of 
responses, going from cell growth and proliferation to survival and motility [48]. Briefly, 
PI3K is activated by receptor protein tyrosine kinases or receptors coupled with G 
proteins. The substrate for class I PI3K is phosphatidylinositol-4,5-biphosphate, leading to 
the production of phosphatidylinositol-3,4,5-triphosphate (PIP3). Then, PIP3 recruits 
signalling proteins, namely AKT (also named protein kinase B) inducing conformational 
changes. Active AKT translocates to the nucleus, mediates the activation and inhibition of 
several targets, leading to cellular survival and proliferation [39] (Figure 4). 
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Figure 4. Schematic representation of the PI3K-AKT signalling pathway in melanoma cells. Extracellular 
signals after interaction of ligand-receptor are transmitted to the interior of the melanoma cells, that activate 
PI3K, leading to phosphorylation of AKT. Finally, AKT migrates to the nucleus where it mediates the 
activation and/or inhibition of several targets. This results in cellular survival, proliferation, and 
differentiation, promoting melanoma progression. 
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 Although in melanoma PI3K itself is rarely mutated [49] or overexpressed [50], 
activation of downstream signalling components, namely AKT, have been implicated in 
melanoma progression [51]. As such, interaction of extracellular signals with the 
respective receptor is transmitted to the interior of melanoma cells, activating 
downstream cascades [39]. This will lead to the activation of AKT which is crucial for 
melanoma progression, through regulation of adhesion molecules [39] (Figure 4). 
Constitutive activation of AKT was observed in melanoma cell lines and melanoma 
samples in different progression stages [52]. Moreover, increased phospho-AKT 
expression is also associated with melanoma progression and worst patient prognosis 
[53]. 
 
 
	 1.3.1.3 Apoptosis dysregulation 
  
 Several studies reported that melanoma cells have low levels of spontaneous 
apoptosis comparatively to other tumour cells (reviewed in [40]). Apoptotic cell death is 
the major underlying mechanism of therapies targeting cancer cells [54]. The two major 
apoptotic pathways, the intrinsic (or mitochondrial) and extrinsic (or death receptor) 
pathways [55] are targets to aberrant pro-survival signalling, which are implicated in 
melanoma resistance to anticancer therapies [56]. 
 Briefly, the intrinsic pathway of apoptosis involves the permeabilization of the 
outer mitochondrial membrane through cooperation of proapoptotic proteins (such as 
Bax, Bak) [57], leading to the release of apoptogenic proteins into the cytosol, namely 
cytochrome c [58]. Once cytochrome c is released it binds to Apaf-1, inducing the 
formation of the apoptosome complex that recruits the initiator caspase 9. This caspase is 
then activated, leading to the activation of executioner caspases, such as caspase 3, 
causing DNA fragmentation [59] (Figure 5). On the other hand, the extrinsic pathway 
involves the activation of membrane death receptors [60]. Upon activation of these 
receptors, caspase 8 is recruited and activated, leading to direct cleavage of downstream 
executioner caspases, including caspase 3 [61] (Figure 5). 
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Figure 5. Schematic representation of the two main molecular pathways leading to apoptosis. In the intrinsic 
pathway, the release of cytochrome c from the mitochondria results in the formation of the apoptosome and 
activation of caspase 9. In the extrinsic pathway upon ligand binding to specific receptors, caspase 8 is 
activated. Caspase 8 and 9 (initiator caspases) then activate downstream caspases such as caspase 3, resulting 
in cell death. 
 
 
 Apoptosis can also be caspase-independent, mostly involving the translocation to 
the nucleus of the mitochondrial protein, apoptosis inducing factor (AIF) [55]. Caspase-
dependent and/or independent processes result in apoptosis and occurrence of 
morphological features, which include cell shrinkage, nuclear fragmentation, and 
membrane blebbing phenotype [62]. 
 In melanoma, apoptotic events are blocked by the overexpression or over-
activation of pro-survival proteins, such as Bcl-2, Mcl-1, Bcl-XL, and inhibitors of 
apoptosis (IAP), namely XIAP and cIAP1 [63]. In fact, the inability of induce apoptosis 
following genetic errors is one of the main features for cancer progression. Moreover, 
failure to activate apoptotic pathways, in response to drug treatment, may explain the 
observed resistance of melanoma to anticancer therapies [64]. Alternative strategies to 
overcome resistance in melanoma cells and, therefore, improve melanoma therapy can be 
the targeting of those overexpressed/over-activated pro-survival proteins or the exploring 
of non-apoptotic cell death mechanisms. 
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	 1.4 Therapies for metastatic melanoma 
 
 Metastatic melanoma is highly resistant to chemotherapy, radiotherapy, hormonal 
therapy and immunotherapeutic approaches (reviewed in [65]). In the last few decades, 
overall survival has improved slightly, mainly due to earlier diagnosis. Nevertheless, no 
significant impact on remission of patients with metastatic melanoma has been made 
despite improvements in response rates achieved with new drugs or new combinations of 
drugs [66]. 
 Dacarbazine is one of the most effective chemotherapeutic agents for metastatic 
melanoma and remains the classical mono-chemotherapeutic regimen used for the 
deadliest form of skin cancer [66]. This alkylating DNA agent is used as a single agent and 
showed an approximately 20% response rate [67]. Although it has low activity in 
monotherapy, intravenous dacarbazine has remained the basis for many 
chemotherapeutic combinations [68], including with cisplatin and tubular toxins. 
However, these combinations had limited impact on overall survival with increased 
toxicity [69]. 
 Anti-microtubular agents, such as paclitaxel (PXT; natural product-based taxane) 
that act through stabilisation of polymerised microtubules, have been reported to have 
modest activity in patients with metastatic melanoma (16.4% response rate) but 
comparable with that of dacarbazine, cisplatin, or interleukin-2 (IL-2) [70]. However, a 
combination of PXT and tamoxifen demonstrated an overall response rate of 24% in phase 
II trial [71]. Interestingly, a phase I/II trial of sorafenib (non-selective B-Raf inhibitor) 
administered in combination with carboplatin and PXT demonstrated preliminary 
antitumor activity in metastatic melanoma with a favorable safety profile [72]. Moreover, 
PXT is currently used on a phase II trial in combination with carboplatin and axitinib, a 
selective second-generation inhibitor of vascular endothelial growth factor (VEGF) 
receptors, on metastatic melanoma patients. However, final data is not yet published 
(Clinicaltrials.gov identifier: NCT01174238). 
 High dose IL-2, an immunodulatory agent, seems to benefit some patients with 
metastatic melanoma, presenting an overall response of 16%, with complete and partial 
responses rates of 6% and 10%, respectively [73]. IL-2 mediates its effects by binding to 
IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for 
immunity. Unfortunately, these more effective rates were found to be also associated with 
greater toxicities [74]. 
 Ipilimumab, a monoclonal antibody that blocks cytotoxic T lymphocyte-associated 
antigen-4, being a negative regulator of T-cells [75], has recently been approved as a single 
agent therapy for the treatment of late stage melanoma. With the approval of ipilimumab, 
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the role of high dose IL-2 remains in question. While the clinical benefit of high dose IL-2 
is roughly similar to ipilimumab, the toxicity is worse and tolerability is less [76]. 
Nevertheless, ipilimumab has relatively modest overall survival improvement, and 
toxicities associated to this therapy can be severe, long-lasting, or both, although most are 
reversible with appropriate treatment [75]. 
 Considering the overall low efficacy of the drugs presented, novel therapies that 
target specific alterations associated with melanoma are being tested for the treatment of 
metastatic melanoma patients [77]. As described previously, one altered pathway in 
melanoma is the MAPK signalling pathway, with mutations in N-Ras and B-Raf being 
essential for tumour growth and maintenance [39]. In fact, tipifarnib (R115777), a Ras 
inhibitor, has shown to have anti-tumour effects in both human cell cultures and in vivo 
model of melanoma [78]. However, tipifarnib never reached clinical trials as a single-
agent and when in combination with the sorafenib (non-selective B-Raf inhibitor), this 
combination did not significant improve sorafenib efficacy [79]. 
 The selective B-Raf inhibitors, vemurafenib and dabrafenib, demonstrated an 
impressive single agent activities against melanoma, in clinical trials [80,81]. However, 
both also showed development of squamous cell carcinomas as side effects [80,81]. 
Patients become resistant to the B-Raf inhibitor treatment, which was attributed to 
reactivation of the MAPK pathway and enhanced tumour growth through c-Raf [82]. 
Therefore, combination therapy with MEK inhibitors may be most adequate, as all 
isoforms of both Ras and Raf signal through MEK, leading to complete inhibition of the 
MAPK pathway. Phase I and II trials of a combined treatment with dabrafenib and 
trametinib (a selective MEK inhibitor) have shown increased progression free survival but 
without significant reduction in the appearance of squamous cell carcinoma [83]. 
 Other molecular targets, which are being investigated as possible therapeutic 
strategies for melanoma, include inhibitors of the PI3K pathway. However, the dual 
PI3K/mammalian target of rapamycin (mTOR) inhibitor, PI-103, promoted 
immunosuppression, in vivo tumour growth and increases in survival of sorafenib-treated 
melanoma cells [84], while sorafenib in combination with temsirolimus (mTOR inhibitor), 
tested in a phase II trial, demonstrated that this combination did not show sufficient 
activity to justify its further use [79]. 
 Limited efficacy of the presented therapies and their increased toxicities 
emphasize, therefore, the importance of developing novel treatment strategies and 
redirect investigations towards new targets. Understanding and overcoming resistance 
pathways, combining current and future agents, identifying biomarkers to improve patient 
selection, and discovering future therapeutic targets will hopefully lead to further 
advances in treatment. 
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	 2. ADENOSINE 
 
 The purine nucleoside adenosine (ADO) is a structural element of nucleic acids and 
has a central role in the energy metabolism of all living organisms. This nucleoside is 
considered a major local regulator of tissue function through the activation of adenosine 
receptors (AR), especially when energy supply cannot fulfil cellular energy demand [85]. 
Moreover, several studies highlight a crucial role for ADO signalling in regulating several 
processes of cancer development [86]. 
 Intracellular ADO is produced either by breakdown of adenosine monophosphate 
(AMP) promoted by the enzyme 5’ nucleotidase (5’NTase), or by the hydrolysis of S-
adenosylhomocysteine (SAH) [87] (Figure 6). Extracellular ADO is formed by AMP 
hydrolysis catalysed by ecto-5’ nucleotidase (ecto-5’NTase) [88]. Nevertheless, levels of 
this nucleoside may also be regulated by nucleoside transporters (NT) [89], which rapidly 
transport ADO into/out of the cell [89] (Figure 6). Metabolism of ADO by phosphorylation 
(forming AMP) or degradation into inosine (INO) is catalysed by adenosine kinase (AK) 
and adenosine deaminase (ADA), respectively [90] (Figure 6). 
 Physiological concentrations of ADO in body fluids are minimal, ranging from 20-
200 nM [91], and are dependent of body energy consumption. Therefore, is not surprising 
that under metabolic stress conditions, such as hypoxia and ischemia, where breakdown of 
adenosine triphosphate (ATP) is enhanced, ADO extracellular levels can reach 
concentrations as high as 30 μM [91]. The concentration of the ADO metabolite, INO, 
follows the fluctuations of ADO levels, resulting in similar levels of ADO and INO [92]. 
Nevertheless, INO can also be independently formed by direct hydrolysis of inosine 
monophosphate (IMP) (Figure 5), being able to bind to AR and initiate intracellular 
signalling events or affect cell function via receptor-independent pathways [93]. 
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Figure 6. Schematic summary of the regulation of intra- and extracellular levels of adenosine (ADO) and 
inosine (INO). Within the cell, ADO is continually recycled depending on energy requirements through 
dephosphorylation and phosphorylation steps mediated by 5′-nucleotidase (5′NTase) and adenosine kinase 
(AK), respectively. ADO can also be generated after the hydrolysis of S-adenosylhomocysteine (SAH). Levels of 
this nucleoside may also be regulated by nucleoside transporters (NT), which rapidly transport ADO via 
facilitated diffusion into/out of the cell. Excess ADO may also be irreversibly deamidated to INO by the 
enzyme adenosine deaminase (ADA). Hydrolysis of inosine monophosphate (IMP) is another source of INO. 
 
 
	 2.1 Adenosine receptors 
 
 The cellular effects of ADO are mediated through activation of a family of four G-
protein-coupled AR, named A1, A2A, A2B, and A3 [94]. These receptors, also termed P1 
receptors, are seven transmembrane glycoproteins that differ in their affinity for ADO, in 
the G proteins recruited, and finally in the activation of downstream signalling pathways 
of target cells (Figure 7). The A1 and A2A display high affinity for ADO while the A2B and A3 
show low affinity for this nucleoside [95]. The A1AR and A3AR, coupled to Gi proteins, 
inhibit the enzyme adenylyl cyclase (AC), thereby decreasing the levels of intracellular 
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cyclic AMP (cAMP) [94]. However, they also activate other intracellular signal 
transducers, such as PKC, PI3K, and ERK1/2 [96]. Additionally, A3AR is also able to signal 
through the PLC pathway via Gq proteins [97]. The A2AAR and A2BAR, coupled to Gs 
proteins, activate AC, leading to the increase of cAMP levels. This increase results in the 
activation of protein kinase A (PKA) pathway [94]. Moreover, A2AAR has been described to 
activate G protein-independent pathways [98] and A2BAR is also able to couple Gq, as well 
as to activate other pathways, such as MAPK and PI3K [96] (Figure 7). Accordingly, MAPK 
and PI3K signalling and hence cell proliferation might be amenable to manipulation 
through specific AR in tumour cells. For a review see [99]. 
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Figure 7. Schematic representation of the four AR subtypes (A1, A2A, A2B, and A3), coupling to G proteins, and 
respective downstream signalling pathways (*:activation; ↑:increase; and ↓:decrease). 
 
 
	 2.2 Adenosine receptors and cancer 
 
 The effects of extracellular ADO are pleiotropic, being the cellular response to this 
nucleoside dependent on the expression of the different AR subtypes on each tissue. They 
can be co-expressed in the same cell, activating different signal transduction pathways. AR 
have been actively studied as potential therapeutic targets in several disorders, including 
cancer (reviewed in [86]). 
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 Increasing evidence indicates that ADO, the end product of ATP hydrolysis, is an 
autocrine and paracrine regulatory factor that can rapidly increase its concentration in 
response to pathophysiological conditions, and therefore may accumulate in the tumour 
microenvironment [100,101]. Indeed, alterations in purine metabolism that facilitate ADO 
production, contribute to tumour development and progression [102]. Moreover, 
increased levels of ADO also contribute to angiogenesis that is essential for tumour growth 
[103]. ADO may regulate tumour growth through both receptor-mediated and receptor-
independent pathways [104]. Extracellular ADO acts mainly through the activation of AR, 
and it is considered a full agonist for all AR [101]. Moreover, reduction of extracellular 
levels of ADO, by an increase in ADA activity, has been also suggested to reduce tumour 
promotion or progression [105]. On the contrary, studies reported that levels of ADA are 
increased in serum of patients with cancer [106]. Nevertheless, ADO also showed growth-
inhibitory effects, and anti-apoptotic or even pro-apoptotic effects, depending on the 
tumour type (reviewed in [101]), suggesting that the activation of AR subtypes involved in 
tumour progression remains largely unknown. Although both in vitro studies and animal 
models have confirmed that targeting AR has tremendous potential for treating cancers 
[100], the translation into clinical practice will require a more thorough understanding of 
how ADO and AR regulate cancer. 
 
 
	 2.2.1 A3AR and melanoma 
 
 The research results to date indicate that in melanoma, activation of A3AR showed 
to have an important role in controlling melanoma growth, showing also that only two 
studies report the involvement A2AAR in murine melanoma cells, through the use of 
antagonists (reviewed in [100]). 
 Targeting A3AR, by ADO or synthetic agonists, has been described to cause 
differential effects on tumour or on normal cells, inhibiting cell growth of various tumour 
types such as melanoma while favours normal cells development [107]. Primary and 
metastatic tumour tissues were found to express high A3AR levels [108]. Interestingly, 
expression of A3AR was found to be low in most body tissues, while it is highly expressed 
in tumour cell lines [109-111], thus suggesting A3AR as a potential target for tumour 
growth inhibition. 
 Expression and pharmacological characterization of A1, A2A, A2B and A3 receptor 
subtypes were described on human melanoma cells, for the first time, in A375 cells, 
showing that A1 and A3 messenger RNAs (mRNAs) were less expressed than A2A and A2B 
mRNAs [109]. The ability of IB-MECA, a selective A3AR agonist, to decrease levels of PKA, 
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a downstream effector of cAMP, and AKT, leading to cell growth suppression, was 
described in mouse B16-F10 melanoma cells [112]. Moreover, activation of A3AR by IB-
MECA in mice melanoma tumours inhibited PKA and AKT signalling proteins, which 
resulted in tumour growth suppression [113]. The ADO analogue, cordycepin (3'-
deoxyadenosine) was also able to inhibit the growth of another mouse melanoma cell line 
(B16-BL6), through A3AR activation [114]. 
 Oral administration of Cl-IB-MECA, also considered a selective A3AR agonist, to 
melanoma-bearing mice, suppressed the development of melanoma lung metastases, 
causing synergistic anti-tumour effect when in combination with cyclophosphamide [115]. 
 The activation of A3AR with Cl-IB-MECA, on human A375 melanoma cells, results 
in PI3K-dependent phosphorylation of AKT, leading to the reduction of basal levels of 
ERK1/2 phosphorylation, which in turn inhibits cell proliferation [116]. However, ADO, 
the natural ligand, displays contradictory effects on A375 cells: it improves cell 
proliferation through A3AR activation, while it may also induce apoptosis and impair cell 
survival via A2AAR signalling pathway, which involves PKC and MAPK [117]. The blocking 
of A3AR, using the selective A3AR antagonist MRE3008F20, decreases VEGF secretion in 
melanoma cells treated with etoposide and doxorubicin, thus improving the ability of the 
chemotherapeutic regimen to block angiogenesis [118]. 
 Although previous studies demonstrated that A3AR agonists, such as IB-MECA or 
Cl-IB-MECA, at micromolar concentrations, induced apoptosis in different tumour cells, 
this was not true for all cells tested. As such, Cl-IB-MECA led to apoptosis in leukemic (30 
μM) and thyroid carcinoma (≥10 μM) cells through A3AR-independent mechanisms [119-
121], suggesting the possibility that these effects are most likely dependent on the 
intracellular level of Cl-IB-MECA. Nevertheless, Cl-IB-MECA is currently being evaluated 
in clinical trials (phase I and phase II) on patients with hepatocellular carcinoma, showing 
good oral bioavailability with no serious drug-related adverse events nor dose-limiting 
toxicities [122]. 
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B. OBJECTIVES 
 
 While primary melanoma is highly curable with surgery, patients with metastatic 
disease carry the worst prognosis [5]. One of the major problems of metastatic melanoma 
has been the lack of efficient treatments [66], which could be related to an incomplete 
understanding of mechanisms that regulate tumour initiation and metastatic progression. 
Indeed, melanoma is the most treatment-resistant human cancer [123], remaining one of 
the greatest challenges in oncotherapy. 
 It is well accepted that the limited success of most current therapeutic strategies 
used in metastatic melanoma is due, at least in part, to cancer cells ability in escaping 
apoptosis, thus leading to drug resistance [40]. Drugs that activate pathways overcoming 
melanoma’s apoptosis resistance and inducing cell death have, therefore, great potential 
for melanoma therapeutic interventions. ADO is being associated to cancer development, 
progression and metastasis [100]. However, mechanisms involved in these processes are 
still poorly understood. Therefore, identifying key regulator agents involved in melanoma 
progression will provide a tool for development of more effective therapies to impair 
metastatic spread. 
 The overall aims of this thesis were to study the role of ADO-AR system in the 
complex interplay of proliferation, cell death and metastatic progression of melanoma 
cells, and to provide clues for the development of new therapeutic approaches, that will 
improve metastatic melanoma treatment. 
 
 In order to achieve these goals, the following specific objectives were pursued: 
 
 Characterization of the AR in human and mouse melanoma cells and 
establishment of each receptor subtype contribution in proliferation and/or 
cytotoxicity in these models. 
 Investigation of the effects of ADO and its metabolic degradation on melanoma 
cells and the mechanisms involved in these effects. 
 Characterization of the metastatic potential of melanoma cells. 
 Evaluation of the cytotoxic and anti-metastatic effects of the combination of Cl-IB-
MECA with the chemotherapeutic agent, PXT, on melanoma cells, and clarification 
of the underlying mechanisms. 
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Abstract 
Melanoma is one of the most aggressive malignant tumours due to its high metastasis incidence 
and resistance to multiple forms of treatment. It has been reported that adenosine (ADO) has 
tumour promoting activities mediated by adenosine receptors (ARs) activation. However, activation 
of A3 adenosine receptor (A3AR) by synthetic agonists induces inhibitory effects on melanoma cell 
growth. 
The present work aimed at evaluating the expression of ARs in human and mouse melanoma cells 
and the proliferative and/or cytotoxic effects induced by ARs activation.  
The presence of ARs in human A375 and C32 and mouse K1735-M2 melanoma cells was 
determined by immunocytochemistry. The proliferative/cytotoxic effects of ADO and selective ARs 
agonists were assessed using the MTT assay (A570). Results showed the presence of the four ARs 
on melanoma cells. However, A3AR evidenced the lowest staining pattern. CPA, CGS 21680 and 
Cl-IB-MECA (0.1–100 nM; 24h) did not affect cell viability of A375 and K1735-M2 cells. For C32 
cells, ADO concentrations (0.1–100 µM; 24 h) promoted cell proliferation up to 117.90±2.52 (n=15; 
p<0.001, from control). This effect was abolished by the selective A3AR antagonist MRS 1220 (100 
nM): 96.07±2.40 (n=3). Cl-IB-MECA (0.1–100 nM) showed a proliferative effect at lower 
concentrations: 100 nM (1h): 14.31%±2.04 (n=18; p<0.05); 0.1 nM (24h): 29.92%±4.80 (n=22; 
p<0.001). The proliferative effect was abolished by MRS 1220 (100 nM). Higher concentrations of 
Cl-IB-MECA (30-100 µM) caused cytotoxicity in C32 cells (EC50(1h)=36 µM and EC50(24h)=70 µM). 
Cytotoxicity effects were not abolished by MRS 1220. Moreover, these effects were not time 
dependent (1-72h). In the presence of NBTI (10 µM), the cytotoxic effect mediated by 50 µM of Cl-
IB-MECA (-38.22±2.48 n=4; p<0.001) was increased (-55.35±2.13; n=4; p<0.001). Our findings 
show for the first time the presence of ARs on human C32 and mouse K1735-M2 melanoma cells. 
A3AR showed the lowest staining pattern. In C32 cells, cell proliferation elicited by exogenous ADO 
seems to be mediated by A3AR. Nanomolar Cl-IB-MECA concentrations increases C32 cell 
proliferation and micromolar concentrations causes a non time-dependent cytotoxicity, not 
mediated by A3AR activation. Moreover, we have gathered evidence that endogenous ADO may 
protect human C32 melanoma cells from the cytotoxicity induced by high concentrations of Cl-IB-
MECA. 
 
Keywords: Adenosine receptors, melanoma cells, Cl-IB-MECA, NBTI. 
 
 
1. INTRODUCTION 
Melanoma has been, in recent decades, one of the cancers with greatest incidence increase in the 
white human population worldwide [1] being the most serious skin cancer due to its high mortality 
rates [2]. Success of systemic therapy of melanoma has been minimal and associated with limiting 
toxicity, which often results in discontinuation of treatment [3]. The development of new and more 
effective strategies for this type of cancer is, therefore, crucial. Studies have shown that adenosine 
(ADO) levels are high in the tumour microenvironment. The physiological concentrations of ADO 
produced under such conditions are sufficient to activate ARs present in tumour cells [4]. A3 
adenosine receptor (A3AR) has been known to be involved in several pathological processes 
including ischemia, inflammation, and tumorigenesis [1]. Therefore, agonists or antagonists to 
A3AR have been considered as drug candidates for the treatment of various human diseases. 
Especially, A3AR agonists IB-MECA and Cl-IB-MECA exhibited potent anti-tumour activity in 
various in vitro and in vivo models [5]. Activation of A3 adenosine receptor (A3AR) by synthetic 
agonists induces inhibitory effects on melanoma cell growth [6]. Here, we aimed at evaluating the 
expression of ARs in human and mouse melanoma cells and the proliferative and/or cytotoxic 
effects induced by ARs activation. 
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2. METHODOLOGY 
Materials 
Hoechst 33258, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), Adenosine, 
CGS21680, CPA and NBTI and all other chemicals employed in this study were of analytical grade 
and purchased from Sigma-Aldrich. Cl-IB-MECA was purchased from Tocris Bioscience. Anti-A1, 
anti-A2A, anti-A2B and anti-A3 were purchased from Santa Cruz Biotechnology Inc. and Alexa Fluor 
488 from Invitrogen Laboratories Inc. 
 
Cell lines and culture conditions 
Human A375 melanoma cells and mouse K1735-M2 melanoma cells were gently provided by Prof. 
Maria Paula Marques (Unidade de Química-Física Molecular, University of Coimbra, Portugal) and 
Dr. Paulo Jorge Oliveira (Centro de Neurociências e Biologia Celular – CNC, University of 
Coimbra, Portugal), respectively. Human C32 melanoma cells were purchased from ECACC 
(Sigma-Aldrich). Cells were cultured in DMEM-HG medium with 10% FBS, penicillin (10000 U/mL) 
and streptomycin (10 mg/mL), pH 7.4. Cells were incubated at 37 ºC in a humidified atmosphere of 
95% air and 5% CO2. All experiments were performed with cells from batches at passage <50. 
 
Adenosine Receptor Subtypes expression determined by immunocytochemistry 
Cells from exponentially growing cultures were seeded in chamber slide systems (3.0 × 104 
cells/cm2), fixed in 4% paraformaldehyde for 10 min at RT and then, incubated with blocking 
solution of BSA (2% in PBS) for 30 min at RT. Then, cells were incubated with anti-ARs (1:300 in 
PBS) overnight at 4 ºC. After cell washing with PBS, incubation with Hoechst 33258 for 15 min 
(RT) followed by Alexa Fluor 488 (1:1000 in PBS) for 1 h (RT) was performed in the absence of 
light. Parallel negatives controls were also performed. Subsequently, cells were analyzed using the 
fluorescence microscope coupled to a digital camera. 
 
Proliferation/Cytotoxicity assay 
Cells were prepared using an initial cell density of 3.0 × 104 cells/cm2. Twenty-four hours after cell 
seeding, ADO or Agonists solutions were added. Control and blank wells were incubated only with 
DMEM-HG. Cell viability was assessed by MTT assay (A570), 24, 48 and 72 h after addition of 
compounds solutions. EC50 values were determined using the program GraphPad PRISM Software 
Inc (version 4.0). Results are expressed as percentage of the respective control (mean±SEM) and 
n denotes the number of experiments performed in triplicate, initiated and processed in parallel; 
p<0,05 was taken to reflect statistically significant differences (Student’s t test). 
 
 
3. RESULTS AND DISCUSSION 
In the present study we have investigated, for the first time, the expression of purinergic P1 
receptors in human C32 and in mouse K1735-M2 melanoma cells by immunocytochemistry (Fig. 
1). Morphological results showed that all subtypes of adenosine receptors (A1, A2A, A2B and A3) are 
present in human C32 and A375 and in mouse K1735-M2 melanoma cells. However, we could not 
establish a profile for all AR subtypes in melanoma cells since the distribution of ARs was not 
similar in the three types of melanoma cells. Nevertheless, images showed that the A3AR has the 
lowest staining pattern of all melanoma cells used in this study. This fact is in agreement with the 
results obtained by RT-PCR, showing that A1 and A3 mRNAs were less expressed then A2A and 
A2B mRNAs in human A375 melanoma cells [7]. However, A3AR has been reported to be highly 
expressed in primary tumours, such as colon carcinoma, breast carcinoma, small cell lung 
carcinoma, pancreatic carcinoma, and melanoma [6]. This is not true for all types of cancer cells: 
human MCF-7 breast cancer cells appeared to be devoid of any detectable amount of ARs, 
whereas human MDA-MB-231 breast cancer cells only express high levels of A2B receptor subtype 
[8].  
ADO is a cell signalling molecule which binds to specific cell surface receptors and modulate 
intracellular signalling, resulting in the regulation of physiological processes. ADO binds and 
activates four AR subtypes, A1, A2A, A2B and the A3. Since most cells express different ARs and 
their activation may lead to opposite effects, selective synthetic agonists are used to induce 
specific effects on particular cell types.  
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A1AR A2AAR A2BAR A3AR Control
Human A375 
melanoma cells 
Hoechst 33258Alexa Fluor 488
Mouse 
K1753‐M2
melanoma cells 
Human C32
melanoma cells 
 
Fig. 1. Adenosine receptor subtypes (A1AR, A2AAR, A2BAR and A3AR) in human A-375 and C32 and mouse K1735-M2 
melanoma cells (magnification of 1000 times - 10x from ocular lens and 100x from objective lens). 
 
To investigate the effects caused by the activation of AR subtypes by the natural ligand (ADO) or 
selective agonists, cytotoxic studies were carried out on human (A375 and C32) and mouse 
(K1735-M2) melanoma cells and the percentage of viable cells (from control) was determined by 
the MTT assay. 
First, we tested the effect of ADO (0.1–100 µM) on human A375 and mouse K1735-M2 melanoma 
cells (data not showed), after 24 h of incubation. Results showed that the natural ligand did not 
significantly affect cell viability, in these conditions. However, exogenous ADO promoted human 
C32 cell proliferation up to 117.90±2.52 (n=15; p<0.001, from control) and this effect was abolished 
by the selective A3AR antagonist MRS 1220 (100 nM): 96.07±2.40 (n=3) (Fig.2). This fact suggests 
that activation of A3AR by the natural ligand is responsible for human C32 melanoma cell 
proliferation. The same effect was reported for colon carcinoma cells [9]. Nevertheless, our results 
showed that this stimulatory proliferation effect is concentration-independent. Extracellular ADO 
could increase up to micromolar range concentrations as the result of the transport and/or diffusion 
of intracellular adenosine, formed from the large pools of intracellular ATP in tumour 
microenvironment [10]. The physiological concentrations of adenosine produced under such 
conditions are sufficient enough to activate ARs present on tumour cells [11]. ADO has been 
previously reported to induce cell proliferation, through AR activation, in human breast cancer [12] 
and melanoma cells [13]. 
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Fig. 2. Effect of increasing concentrations of ADO (0.1–100 µM) on human C32 melanoma cells, after 24h of incubation; 
and in the presence of a selective A3AR antagonist, MRS 1220 (100 nM). 
 
Thereafter, to better evaluate if ARs activation could interfere with cell proliferation and/or cell 
death, cells were treated with selective agonists. Increasing concentrations of CPA, CGS21680 
and Cl-IB-MECA (selective A1, A2A and agonist A3 agonists, respectively) did not cause significant 
effects in human A375 and mouse K1735-M2 melanoma cell viability, after 24 h of incubation (Fig. 
3). The lack of a selective A2B agonist did not allow us to evaluate the role of this adenosine 
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receptor subtype on these cell lines. For human C32 melanoma cells, CPA and CGS21680 also did 
not cause any effect on cell viability (data not showed). 
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Fig. 3. Effect of increasing concentrations (1-100 nM) of CPA, CGS21680 and Cl-IB-MECA (selective A1AR, A2AAR and 
A3AR agonists, respectively) on cell viability of human A-375 and mouse K1735-M2 melanoma cells, after 24 hours of 
incubation (n=3). 
 
Based on the fact that ADO induced C32 cell proliferation mediated by A3AR activation, we 
examined the effect of increasing concentrations of Cl-IB-MECA in these cells (Fig.4a). 
Concentrations of this selective A3AR agonist in the nanomolar range (0.1-100 nM) promote cell 
proliferation after 24 h of incubation (0.1 nM: 29.92%±4.80 (n=22; p<0.001)). This result was also 
observed immediately after 1 h of incubation with the A3AR agonist (100 nM: 14.31%±2.04 (n=18; 
p<0.05), data not showed). In view of the fact that Cl-IB-MECA is a synthetic nucleoside with anti-
tumour activity [14] we also tested higher concentrations of Cl-IB-MECA (micromolar range) to 
evaluate if it causes a cytotoxic effect on C32 melanoma cells. Micromolar concentrations of Cl-IB-
MECA (30-100 µM) exhibit a cytotoxic effect on human C32 melanoma cells with an EC50 of 36 µM 
(1 h of incubation, data not showed) and an EC50 of 70 µM after 24 h of incubation (Fig.4a). The 
selective A3AR agonist, Cl-IB-MECA, showed a biphasic effect for different concentrations 
(proliferation/cytotoxicity) on human C32 melanoma cells (Fig.4a). The proliferative effect caused 
by Cl-IB-MECA was abolished by a selective A3AR antagonist, MRS 1220 (100 nM, Fig.4b). On the 
contrary, cytotoxicity effects produced by Cl-IB-MECA in human C32 melanoma cells were not 
prevented by MRS 1220 (Fig. 4b). A similar biphasic effect of Cl-IB-MECA was also reported in 
human Caco2 and DLD1 colon cancer cells, after 24 h of incubation with the agonist [9]. Moreover, 
in astrocytoma cells, Cl-IB-MECA promotes protection against apoptosis through A3AR activation 
and promotes cell death of micromolar concentrations, which is not mediated by A3AR [15]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Effect of increasing concentrations of Cl-IB-MECA (0,1 nM – 100 µM) in C32 cells after 24h of incubation (a) and in 
the presence of a selective A3AR antagonist, MRS 1220 (100 nM (b)). 
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In addition, increasing concentrations of Cl‑IB‑MECA (5–80 µM, 24 h) in NPA cells (human 
papillary thyroid carcinoma) also inhibited cell proliferation, by a mechanism independent of 
classical adenosine receptors [16]. The different effects exhibited by nanomolar and micromolar 
concentrations of Cl-IB-MECA could be explained by loss of A3AR selectivity (possible activation of 
other adenosine subtypes receptor) and/or A3AR desensibilization [17]. 
After evaluation of the effect caused by increasing concentrations of Cl-IB-MECA on human C32 
melanoma cells, we tested the dependence of a lower and intermediate EC50 concentrations (10 
and 50 µM) over time (1h-72h, Fig.5). After each incubation time, we found that Cl-IB-MECA did 
not induce a time-dependent cytotoxicity. The same was true for recent selective A3AR agonist, 
Thio-Cl-IB-MECA (0-100 µM), in human lung cancer cells [18]. 
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Fig. 5. Effect of Cl-IB-MECA (10 and 50 µM) on C32 cells after 1, 24, 48 and 72 h of incubation. 
 
We also verified the possibility of Cl-IB-MECA can act intracellulary, as a second messenger, after 
being transported into the cells. NBTI, a nucleoside transporter inhibitor, used at a final 
concentration of 10 µM, which is an excess of IC50 values for inhibition of nucleoside transporters 
[19] failed to inhibit or reduce the effects of 50 µM Cl-IB-MECA (-38.22±2.48 n=4; p<0.001) (Fig. 6). 
This result is consistent with what was described for human NPA thyroid cancer cells: 40 µM of Cl-
IB-MECA inhibited cell proliferation by neither A3AR activation nor through a nucleoside 
transporter-dependent mechanism [16]. On the contrary, our results reveal an increase in the 
cytotoxic effect caused by the addition of 10 µM of NBTI to 50 µM of Cl-IB-MECA (-55.35±2.13; 
n=4; p<0.001), which suggest that endogenous ADO can protect human C32 melanoma cells 
against cell death. Perhaps, in the presence of NBTI, endogenous ADO was unable to access the 
extracellular space, activate the A3AR and promote cell proliferation. 
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Fig. 6. Effect of Cl-IB-MECA (50 µM) on C32 cells in the presence and absence of NBTI (10 µM), after 24 h of incubation. 
 
 
4. CONCLUSIONS 
To our knowledge, our findings show for the first time, the presence of all four AR subtypes (A1AR, 
A2AAR, A2BAR and A3AR) on human C32 and mouse K1735-M2 melanoma cells. Moreover, a 
sparser presence of A3R was observed in the three studied melanoma cells lines (human A375 and 
C32 and mouse K1735-M2 cells), when compared to the other AR subtypes. The selective AR 
agonists CPA (A1AR), CGS 21680 (A2AAR) and Cl-IB-MECA (A3AR) did not affect cell viability in 
human A-375 and mouse K1735-M2 melanoma cells. 
Human C32 melanoma cell proliferation elicited by exogenous ADO seems to be mediated by 
A3AR. Nanomolar Cl-IB-MECA concentrations increased C32 cell proliferation; micromolar Cl-IB-
MECA concentrations caused cytotoxicity which was neither time-dependent, nor mediated by 
A3AR. Endogenous ADO may protect cells from the cytotoxicity induced by high concentrations of 
Cl-IB-MECA. These results further highlight the therapeutic potential of Cl-IB-MECA in melanoma. 
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Abstract 
Malignant melanoma is the most deadly type of skin cancer. The lack of effective 
pharmacological approaches could be related to the incomplete understanding of the 
pathophysiological mechanisms involved in cell melanoma proliferation. Adenosine has 
growth-promoting and growth-inhibitory effects on tumour cells. We aimed to investigate 
effects of adenosine and its metabolic product, inosine, on human C32 melanoma cells and 
the signalling pathways involved. 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction and 
bromodeoxyuridine (BrdU) proliferation assays were used to evaluate adenosine, 
adenosine deaminase and inosine effects, in the absence or presence of AR, A3AR and 
P2Y1R antagonists; and PLC, PKC, MEK1/2, and PI3K inhibitors. ERK1/2 levels were 
determined using an ELISA kit. Adenosine and inosine levels were quantified using an 
enzyme-coupled assay. 
Adenosine caused cell proliferation through AR activation. Adenosine deaminase 
increased inosine levels (nanomolar concentrations) on the extracellular space, in a time-
dependent manner, inducing proliferation through A3AR activation. Micromolar 
concentrations of inosine enhanced proliferation through A3AR activation, causing an 
increase in ERK1/2 levels, and P2Y1R activation via ENT-dependent mechanisms. 
We propose the simultaneous activation of PLC-PKC-MEK1/2-ERK1/2 and PI3K 
pathways as the main mechanism responsible for the proliferative effect elicited by inosine 
and its significant role in melanoma cancer progression. 
 
Keywords: Inosine, proliferation, melanoma, A3AR, ERK1/2, PI3K. 
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Abbreviations 
AC: adenyl cyclase 
ADA: adenosine deaminase 
ADO: adenosine 
AK: adenosine kinase 
AMP: adenosine monophosphate 
AOPCP: adenosine 5′-(α,β-methylene)diphosphate 
AR: adenosine receptor 
ATP: adenosine triphosphate 
BrdU: bromodeoxyuridine 
cAMP: cyclic AMP 
CD73: ecto-5'-nucleotidase 
CGS 19543: 5-amino-9-chloro-2-(2-furyl)1,2,4-triazolo[1,5-c]quinazoline 
CNTs: Na+-dependent concentrative nucleoside transporters 
CTR: control 
DMSO: dimethyl sulfoxide 
DMEM-HG: dulbecco's modified eagle's medium – high glucose 
ENTs: Na+-independent equilibrative nucleoside transporters 
ERK: extracellular signal-regulated kinase  
FBS: foetal bovine serum 
H89: N-[2-[[3-(4-bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinolinesulfonamide 
dihydrochloride 
HRP: horseradish peroxidase 
INO: inosine 
ITU: 5-iodotubericidin 
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LY294002: 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride 
MAPK: mitogen-activated protein kinase  
MEK: mitogen-activated protein kinase kinase  
MRE 3008F20: N-[2-(2-furanyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidin-5-yl]-N'-(4-methoxyphenyl)urea 
MRS 2500: N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5-bisphosphate 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NBTI: 6-S-[(4-nitrophenyl)methyl]-6-thioinosine 
NT: nucleoside transporters 
P2Y1R: P2Y1 receptor 
PI3K: phosphoinositide 3-kinase 
PKA: protein kinase A 
PKC: protein kinase C 
PLC: phospholipase C 
PNP: purine nucleoside phosphorylase 
RO 32-0432: 3-[(8S)-8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-
yl]-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione hydrochloride 
U0126: 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene 
U73122: 1-[6-[[(17β)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-
dione 
U73343: 1-[6-[[(17β)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-2,5-
pyrrolidinedione 
XO: xanthine oxidase 
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Introduction 
Malignant melanoma is the most deadly type of skin cancer. Although melanoma is less 
common than other types of skin cancers, the incidence of cutaneous melanoma is rising 
faster than any other solid tumour [1], accounting for a global incidence of about 160 
thousands new cases each year [2]. This increased incidence may be a consequence of 
more people chronically exposed to natural/artificial UV radiation and/or as a result of 
higher detection rates associated with enhanced public awareness [3]. While primary 
melanoma is highly curable with surgery, patients with metastatic disease carry the worst 
prognosis, with a median survival time of less than 1 year [3]. One of the major problems 
of metastatic melanoma has been the lack of efficient treatments [4]. The absence of an 
effective pharmacological approach could be, at least in part, due to an incomplete 
understanding of the pathophysiological mechanisms involved in melanoma cells 
proliferation and, ultimately, tumour initiation and progression. 
Melanoma progression is associated to abnormal activation of pathways that regulate the 
proliferation of melanocytes [5]. Mitogen-activated protein kinase (MAPK) and 
phosphoinositide 3-kinase (PI3K) pathways are constitutively activated in most melanomas 
[2, 6]. 
Increasing evidence indicates that complex interactions of tumour cells with the tumour 
microenvironment may be related with secretory products released by these cells, which 
appear to be fundamental for tumourigenesis [7]. Adenosine (ADO), the end product of 
adenosine triphosphate (ATP) hydrolysis, is one of those trophic products, being increased 
in the tumour microenvironment [reviewed in [8]]. High levels of extracellular ADO are 
caused, at least in part, by the ecto-5'-nucleotidase (CD73), overexpressed in various types 
of cancer, which catalyses the hydrolysis of extracellular adenosine monophosphate 
(AMP) into ADO [9]. This nucleoside may then regulate the growth and development of 
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tumour cells through adenosine receptor (AR)-dependent and/or independent pathways 
[10]. 
Extracellular ADO acts mainly through the activation of four subtypes of AR (A1, A2A, 
A2B, and A3), members of the G protein-coupled receptor superfamily, and it is considered 
a full agonist for all AR [8]. Stimulation of A3AR, which is upregulated in different 
tumours, by ADO is reported to have distinct and tumour specific actions, since ADO can 
have growth-promoting as well as growth-inhibitory effects, anti-apoptotic or even pro-
apoptotic effects, depending on the tumour type [reviewed in [8]]. 
Alternatively to AR-mediated actions, ADO may be rapidly transported into the cell by 
nucleoside transporters (NT). Two major types of NT have been distinguished based on 
their mechanism of action: Na+-dependent concentrative nucleoside transporters (CNTs), 
active transport; and bidirectional Na+-independent equilibrative nucleoside transporters 
(ENTs), passive transport [11, 12]. Additionally, the expression of these transporters is 
found to be changed in certain tumours. Once inside the cell, ADO can be converted to 
AMP via adenosine kinase (AK) or to inosine (INO) via adenosine deaminase (ADA) [13]. 
Nevertheless, INO can be formed both intracellular and extracellularly, and it can also bind 
to AR and initiate intracellular signalling events or affect cell function via receptor-
independent pathways [14]. 
Evidence suggests that an increase in ADA activity can cause a reduction in the 
concentration of ADO in the extracellular medium, thus reducing tumour promoting 
functions [15]. However, serum ADA has been shown to be increased in patients with 
bladder [16], breast [17], and lung cancer [18]. ADA serum levels in patients with 
melanoma were never evaluated and a full study of the effects of its metabolic product 
(INO) in human melanoma cells is still lacking.  
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The purpose of the present work was to investigate the effects of ADO and particularly of 
its metabolic product INO, on human C32 melanoma cells and to gather further insights 
into the signal transduction pathways involved. We report that INO caused cell growth 
mainly through the direct activation of A3AR. Surprisingly, indirect P2Y1R activation also 
contributes to the INO-induced proliferative effect. Intracellularly, INO-induced 
proliferation is due to the simultaneous activation of PLC-PKC-MEK1/2-ERK1/2 and 
PI3K pathways as the molecular mechanisms able to explain the proliferative activity of 
INO on human C32 melanoma cells. 
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Materials and Methods 
Chemicals 
MRE 3008F20, CGS 15943, MRS 2500, and pentostatin were obtained from Tocris 
Bioscience (Bristol, United Kingdom). Bromodeoxyuridine (BrdU) cell proliferation assay 
kit and STAR ERK1/2 ELISA kit were purchased from Merck-Millipore (Interface, 
Amadora, Portugal). Bio-Rad RC DC protein assay kit was purchased to Biorad (Amadora, 
Portugal). Foetal bovine serum (FBS), Glutamax, and Trypsin/EDTA were obtained from 
Gibco – Invitrogen, Alfagene (Carcavelos, Portugal). Dulbecco's Modified Eagle's 
Medium – High Glucose (DMEM-HG), penicillin/streptomycin (10 000 U/mL; 10 
mg/mL), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), dimethyl 
sulfoxide (DMSO), 5-iodotubericidin (ITU), adenosine 5′-(α,β-methylene)diphosphate 
(AOPCP), 6-S-[(4-Nitrophenyl)methyl]-6-thioinosine (NBTI), dipyridamole, RO 32-0432, 
U73343, U73122, H89, U0126, LY294002, ADA type X (EC 3.5.4.4), purine nucleoside 
phosphorylase (PNP; EC 2.4.2.1), xanthine oxidase (XO; EC 1.17.3.2), horseradish 
peroxidase (HRP; EC 1.11.1.7), Amplex Red reagent, ADO, INO, hypoxanthine, uridine, 
and all other chemicals were purchased from Sigma-Aldrich (Sigma-Aldrich-Química SA, 
Sintra, Portugal) of the highest purity available.  
 
Melanoma cell culture 
Human C32 melanoma cells obtained from ECACC - SIGMA (Sigma-Aldrich-Química 
SA, Sintra, Portugal) were used in this study. Cells were seeded in DMEM-HG medium 
with 10% of FBS, 1% of a mixture of penicillin/ streptomycin (10 000 U/mL; 10 mg/mL) 
and 1% of Glutamax, pH 7.4. Cells were incubated at 37 ºC in a humidified atmosphere 
(95% air; 5% CO2). For cell culture maintenance, cells were grown in monolayer and sub-
cultivated twice a week. Cell passaging was done by trypsinization. All experiments were 
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carried out with cells at 70−80% confluence and from batches with passage number lower 
than 50. 
 
Cell treatment 
Human C32 melanoma cells were prepared using an initial cell density of 5.0 × 104 
cells/cm2. Cells were allowed to attach for 24h and then were treated with ADA [0.3 U/mL 
[19]] or increasing concentrations of nucleosides (ADO or INO) for different time-points 
(1 – 48h), depending on the experiment performed.  When antagonists [MRE 3008F20 
(selective A3AR, 10 nM [20]); CGS 15943 (non-selective AR, 100 nM [20]); MRS 2500 
(selective P2Y1R, 1 µM [21]] were used, these compounds were added 30 min prior to the 
addition of other compounds. 
Experiments with ENTs inhibitors [dipyridamole and NBTI, 10 µM [22]] were performed 
incubating cells with these inhibitors for 1h, before the addition of other compounds (for 
dipyridamole), or 15 min after addition of pentostatin plus ITU (for NBTI), since NBTI 
also prevents pentostatin [23] and ITU [22] uptake. Simultaneous addition of uridine [300 
µM [24]] with INO was performed when this substrate for ENTs and CNTs was used. 
Pentostatin [ADA inhibitor, 10 nM [25]], ITU [adenosine kinase (AK) inhibitor, 100 nM 
[22]], AOPCP [CD73 inhibitor, 100 µM [26]], U-73122 [selective phospholipase C (PLC) 
inhibitor, 1 µM [27, 28]], U-73343 [selective PLC inhibitor analogue, 1 µM [27]], RO 32-
0432 [selective PKC inhibitor, 1 µM [27]], H-89 [selective PKA inhibitor, 1 µM [27]], 
U0126 [selective MEK1/2 inhibitor, 10 µM [29, 30]] and LY294002 [potent PI3K 
inhibitor, 1 µM [31, 32]] were added 1h prior to the addition of other compounds. 
All conditions, including vehicle (cells exposed to DMSO at maximum final concentration 
of 0.1% v/v) and blank (without cells) wells were initiated and processed in parallel. 
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MTT reduction assay 
C32 cells were seeded in 96-well plates. After cell treatment, mitochondrial function was 
evaluated as an index of cell proliferation or cytotoxicity, since mitochondrial 
dehydrogenases of living cells can reduce the MTT (yellow) to formazans [33]. At the end 
of the incubation (48h), cells were processed as already described by us [20]. 
 
Determination of ERK1/2 levels 
C32 cells were seeded in 6-well plates. After cell treatment, quantitative evaluation of 
ERK1/2 levels was done with the STAR ERK1/2 ELISA kit, according to the 
manufacturer’s instructions, after 24h incubation. 
 
Protein content determination 
Protein content of cellular fractions in total cell lysates for ERK1/2 assays was determined 
using the Bio-Rad RC DC protein assay kit, in accordance to the manufacturer instructions. 
Stock solutions of bovine serum albumin were used as standards. 
 
BrdU proliferation assay 
C32 cells were seeded in 96-well plates. After cell treatment, BrdU was added to the cells 
5h prior to the end of the incubation period (48h). Quantitative detection of newly 
synthesized DNA of actively proliferating cells was determined with the BrdU kit, 
according to the manufacturer’s instructions. 
 
Metabolism of ADO and INO 
Cells were incubated at 37 ºC in 24-well plates in the absence and presence of ADA (0.3 
U/mL). After 1h, 6h and 48h incubation, cell medium was collected, immediately heat-
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inactivated (5 min at 60 ºC) and assayed for ADO and INO levels, as specified in the 
enzyme-coupled assay (fluorometric detection) developed by Helenius et al. [19]. Stock 
solutions of ADO, INO, and hypoxanthine were used as standards. Calibrations curves 
were generated for each experiment using identical coupled reactions. 
 
Statistical analysis 
Results are presented as mean ± SEM for n experiments. Statistical comparisons between 
groups were performed with One-Way ANOVA, after Shapiro-Wilk test normality 
evaluation. Significance was accepted at p values <0.05. The Student–Newman–Keuls post 
hoc test was used once a significant p was achieved. 
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Results 
Micromolar concentrations of exogenous ADO causes proliferation of human C32 
metastatic melanoma cells through AR activation 
Cells were exposed to increasing concentrations of ADO (0.1–1000 μM) and 
mitochondrial functionality of these cells was evaluated at 48h (Figure 1A). A significant 
increase in cell proliferation, indicated by the MTT reduction assay, was already observed 
for the lowest ADO concentration tested (0.1 μM, p<0.001), when compared to vehicle. 
Furthermore, concentrations of ADO up to 100 μM caused a significant increase in cell 
proliferation (p<0.001), when compared to vehicle. However, this effect was not 
concentration-dependent. For the highest ADO concentration used (1000 μM), MTT 
reduction assay showed mitochondrial dysfunction (p<0.01, comparatively to vehicle), 
indicating that this concentration is cytotoxic. 
To investigate whether exogenous ADO elicited proliferative/cytotoxic effects on human 
C32 melanoma cells through AR activation, cells were incubated with the same 
concentrations of ADO (0.1–1000 μM), in the presence of CGS 15943, a potent and non-
selective AR antagonist, for 48h (Figure 1A). CGS 15943 completely blocked the 
proliferative effect caused by concentrations of ADO up to 100 µM. These results suggest 
that, C32 cells proliferation caused by exogenous ADO (0.1–100 µM) is mediated by AR 
activation. However, CGS 15943 was not able to prevent the cytotoxicity elicited by the 
highest ADO concentration tested (1000 μM), suggesting that the cytotoxic effects caused 
by millimolar concentrations of ADO, on human C32 melanoma cells, are not AR-
mediated. 
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Increased endogenous ADO has AR-dependent proliferative effects on human C32 
melanoma cells 
Cells were incubated with the ADA inhibitor, pentostatin (10 nM), alone or in combination 
with the AK inhibitor, ITU (100 nM), in order to evaluate whether similar effects could be 
triggered by endogenous ADO. The proliferative ability of C32 cells was evaluated at 48h 
(Figure 1B). Significant increase in cell proliferation was observed for C32 cells treated 
with pentostatin (p<0.001) or ITU (p<0.01), when compared to vehicle. This effect was 
even more pronounced when cells were treated simultaneously with pentostatin and ITU 
(p<0.01, comparatively to pentostatin alone). These results confirm that when enzymes 
involved in ADO catabolism are inhibited, endogenous ADO levels are involved in the 
enhancement of cell proliferation. 
In order to examine whether increased levels of endogenous ADO induces proliferation of 
human C32 melanoma cells by intracellular or extracellular mechanisms, cells were pre-
treated with pentostatin (10 nM) and ITU (100 nM), and then incubated with the 
bidirectional ENT inhibitor (10 µM of NBTI), for 48h (Figure 1B). NBTI completely 
blocked the proliferative effect caused by the combination of pentostatin and ITU 
(p<0.001), indicating that proliferation of C32 cells is caused by extracellular ADO. 
To assess whether AR activation has any relevant role in the observed cell proliferation 
caused by the increased levels of endogenous ADO in the extracellular space, MTT test 
was performed in cells pre-treated with 100 nM of CGS 15943 and incubated with 
pentostatin in combination with ITU. CGS 15943 completely blocked the proliferative 
effect caused by the extracellular accumulation of endogenous ADO (p<0.001, Figure 1B). 
Overall, results suggest that C32 cells proliferation caused by endogenous ADO is 
mediated by AR activation. These data are in agreement with the results obtained with 
exogenously added ADO. 
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Additionally, in order to prevent ADO production, an inhibitor of CD73 (AOPCP, 100 
µM) was added, (Figure 1B). AOPCP induced cytotoxic effects on C32 cells (p<0.001, 
comparatively to vehicle), after 48h incubation, demonstrating the importance of 
endogenous ADO on the proliferation and survival of these cells. 
 
Metabolic product of exogenous ADA causes human C32 melanoma cells proliferation 
through A3AR activation 
Effects of ADO catabolism (through the addition of ADA) and consequent increased levels 
of its metabolic product (INO) were studied on C32 cells. Cells were treated with 
pentostatin (10 nM) plus ITU (100 nM) and with ADA (0.3 U/mL) for 48h. Surprisingly, 
results obtained by the MTT reduction assay indicated that addition of ADA did not reduce 
the proliferative effect caused by increased levels of endogenous ADO, after co-incubation 
of pentostatin and ITU (Figure 2). The effect of ADA alone showed that degradation of 
endogenous ADO leads to a significant increase on C32 proliferation (p<0.001, 
comparatively to vehicle), suggesting that not only ADO but also its ADA metabolic 
product, INO, are able to induce proliferation of these cells. 
In order to evaluate whether endogenous INO induces proliferation of human C32 
melanoma cells through intracellular or extracellular mechanisms, cells were treated with 
ADA, in the presence of the ENT inhibitor, dipyridamole, which prevents the uptake of 
nucleosides. Cells were pre-treated with dipyridamole (10 µM), and then incubated with 
ADA for 48h. This ENT inhibitor could not prevent the cell proliferation caused by the 
addition of ADA (Figure 2). This result indicates that the proliferative effect induced by 
INO is mainly due to the extracellular accumulation of INO rather than an intracellular 
mechanism. 
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To assess whether AR activation has any relevant role in the proliferation observed by 
increased extracellular levels of INO, cells were pre-treated with the non-selective AR 
antagonist, CGS 15943 (100 nM) or the selective A3AR antagonist, MRE 3008F20 (10 
nM) after which cells were incubated with ADA for 48h. CGS 15943 completely blocked 
the proliferation caused by endogenous INO (p<0.001, Figure 2). Similar results were 
obtained for the selective A3AR antagonist, MRE 3008F20 (p<0.001, Figure 2). Taken 
together, these results demonstrate that endogenously produced INO also promotes C32 
cell proliferation through A3AR activation. 
 
Exogenous INO enhances proliferation of human C32 melanoma cells by direct A3AR 
activation and indirect P2Y1R activation through ENT-dependent mechanisms 
To evaluate the effect of exogenous INO on C32 cells and compare with the observed 
effects of exogenous ADO, cells were incubated with two concentrations of INO (50 and 
100 µM) for 48h (Figure 3). Results of MTT test on C32 cells treated with INO 
demonstrated significant cell proliferation, when compared to vehicle (p<0.001; Figure 3). 
However, this proliferative effect was not concentration-dependent. This observation is 
similar to the effect elicited by exogenous ADO, although exogenous INO caused a higher 
increment on the C32 cells proliferation percentage (in similar concentrations) than 
exogenous ADO on the same model and incubation period. 
Since endogenously formed INO induces C32 cell proliferation by activation of A3AR, 
experiments were carried out in order to determine whether exogenous INO could also 
mediate cell proliferation via AR-mediated mechanisms. To address this goal, cells were 
pre-treating with MRE 3008F20 (10 nM) or CGS 15943 (100 nM) and then incubated with 
INO (50 µM) for 48h. Both selective A3AR and non-selective AR antagonists, were only 
able to partially and to the same extent block proliferation caused by 50 µM of INO 
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(p<0.001; Figure 3). This fact suggests that, although most of the proliferation caused by 
exogenous INO is mediated by A3AR activation, other mechanisms may also be involved 
in the INO-induced proliferative effect (at this INO concentration). As such, cells were 
treated with INO (50 µM) in the presence of uridine (300 µM), a substrate for ENTs and 
CNTs. Simultaneous addition of uridine and INO, for 48h, caused approximately 21% 
inhibition of proliferation of C32 cells (p<0.05; Figure 3), suggesting that the proliferative 
effect caused by INO is also nucleoside transporters (NT)-dependent. To assess whether 
this effect was mediated by ENTs or CNTs, cells were pre-treated with the ENTs inhibitor, 
dipyridamole (10 µM), and then incubated with INO (50 µM) for 48h. Dipyridamole 
blocked approximately 24% of C32 cells proliferation caused by the addition of INO 
(p<0.05; Figure 3), similar to the inhibition percentage elicited by uridine. These results 
confirmed the role of INO uptake mediated by ENTs on proliferation of C32 cells. In an 
attempt to clarify which possible intracellular mechanisms could be involved in the 
proliferative effect caused by exogenous INO, cells were also pre-treated with the selective 
P2Y1R antagonist (MRS 2500, 1 µM) in the presence of 50 µM of INO (Figure 3): results 
showed that MRS 2500 was not able to completely block the INO-induced proliferative 
effect (p<0.05), with an inhibition percentage similar to those caused by the ENT inhibitor; 
when cells were co-incubated with the selective A3AR and P2Y1R antagonists, the 
proliferative effect elicited by INO was completely blocked. In addition, the combination 
of these two antagonists, in the absence of added INO, caused a significant C32 cells 
cytotoxicity (p<0.05), indicating that A3AR and P2Y1R are constitutively activated in these 
melanoma cells. 
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Simultaneous activation of PLC-PKC-MEK-ERK and PI3K pathways are the main 
mechanisms responsible for the proliferative effect of exogenous INO 
To get further insights on the intracellular mechanisms that cause proliferation of human 
C32 melanoma cells elicited by exogenous INO (50 µM), cells were pre-treated with the 
PKA inhibitor, H-89 (1 µM) for 48h. The proliferative effect of added INO was not 
blocked nor attenuated by H-89, indicating that PKA signalling pathway does not 
contribute to the observed proliferative effect (data not shown). 
C32 cells were then incubated with 50 µM of INO in the absence or in the presence of 
inhibitors of PLC (U-73122), PKC (RO 32-0432), MEK1/2 (U0126) and PI3K 
(LY294002) to evaluate proliferation after 48h. Figure 4A showed that the proliferative 
effect caused by INO was significantly decreased by 1 µM of PLC inhibitor 
(approximately 67%), but not by its inactive analogue U-73343 (1 µM). The PKC inhibitor 
(1 µM) and the MEK1/2 inhibitor (10 µM) also counteracted the INO-induced proliferating 
effect (approximately 65% and 68%, respectively). These data suggest that PLC-PKC-
MEK1/2 pathway has a significant role on INO-mediated proliferation of C32 cells. 
However, it was not the only pathway involved since total ablation of the effects was not 
achieved. Therefore, human C32 melanoma cells were incubated with INO after a pre-
treatment with 1 µM of LY294002 (PI3K inhibitor). This pre-treatment attenuated (~32%) 
the proliferative effect (Figure 4A). When INO was tested in the presence of combinations 
of PLC and PI3K inhibitors (U-73122 plus LY294002) or MEK1/2 and PI3K inhibitors 
(U0126 plus LY294002), the proliferative effect was completely blocked, suggesting that 
micromolar concentration of exogenous INO caused proliferation of human C32 melanoma 
cells through simultaneous activation of PLC-MEK1/2 and PI3K pathways. Moreover, the 
inhibitors combinations tested, in the absence of added INO, caused significant C32 
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cellular cytotoxicity (p<0.05), indicating that PLC- MAPK and PI3K pathways are 
constitutively activated in these human melanoma cells. 
To evaluate the role of ERK1/2 expression, final molecule of MEK pathway, on C32 cell 
proliferation induced by exogenous and endogenous INO, cells were treated with INO (50 
μM) or ADA (0.3 U/mL) in the absence or in the presence of the selective A3AR 
antagonist (MRE 3008F20, 10 nM), the MEK1/2 inhibitor (U0126, 10 µM) or the PI3K 
inhibitor (LY294002, 1 µM) for 24h. Increased levels of ERK1/2, obtained with the 
ELISA kit, are dependent on A3AR and MEK1/2 activation, since only MRE 3008F20 and 
U0126 were able to completely block the increased levels of ERK1/2 induced by 
endogenous and exogenous INO (Figure 4B). Involvement of PI3K pathway on rising 
ERK1/2 levels was excluded because LY294002 was not able to block the increase in 
ERK1/2 levels (Figure 4B), thus demonstrating that PI3K activation occurs independently. 
 
BrdU cell proliferation assay confirms the INO-induced proliferative effects on human 
C32 melanoma cells 
The golden standard assay for cell proliferation, BrdU assay, was performed to confirm 
whether the results obtained by the MTT reduction assay were, in fact, representative of 
cell proliferation. For this purpose only conditions considered crucial were tested. Human 
C32 melanoma cells were pre-treated with selective A3AR and/or P2Y1R antagonists (10 
nM of MRE 3008F20 and 1 μM of MRS 2500, respectively) and then incubated with INO 
(50 µM) for 48h. As shown in Figure 5, exogenous INO significantly enhanced C32 cells 
proliferation (p<0.001), when compared to vehicle, confirming those proliferative effects 
obtained using the MTT reduction assay (Figure 3). MRE 3008F20 was not able to 
completely block the proliferative effect caused by 50 µM of INO (approximately 77 %; 
Figure 5). Total prevention of this effect was only achieved when cells were pre-treated 
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with the combination of the A3AR and P2Y1R antagonists, thus corroborating the results 
already obtained with the MTT test. 
Activation of MEK1/2 in proliferation of cells induced by exogenous INO was also 
confirmed with the BrdU test. Cells were pre-treated with the MEK1/2 inhibitor, U0126 
(10 µM) and then incubated with INO (50 µM) for 48h. Results confirm the involvement 
of MAPK pathway in the proliferation of C32 cells, already suggested by the MTT test 
(approximately 68%; Figure 4A), since MEK1/2 inhibitor was only able to partially block 
the INO-induced proliferative effect (approximately 72%; Figure 5). 
Crucial conditions for endogenous INO (addition of ADA) already tested with the MTT 
test were also confirmed with the BrdU test: ADO deamination catalysed by ADA 
significantly enhanced C32 cells proliferation (p<0.001), when compared to vehicle 
(Figure 5). In cells pre-treated with the selective A3AR antagonist (MRE 3008F20, 10 nM) 
or the MEK1/2 inhibitor (U0126, 10 µM), and then incubated with ADA (0.3 U/mL) for 
48h, cell proliferation was also completely blocked (p<0.001; Figure 5), as in MTT test. 
 
Exogenous ADA increases INO levels on the extracellular space in a time-dependent 
manner 
Quantification of extracellular ADO and INO levels was performed using an enzyme-
coupled assay, in order to determine the concentrations of endogenous ADO and INO 
present in the cellular medium with or without addition of ADA (Figure 6). Results 
showed that extracellular concentrations of ADO (Figure 6A) and INO (Figure 6B) were in 
the nanomolar range. For both vehicle and ADA conditions, ADO concentrations 
decreased with time (Figure 6A). For the vehicle condition, a starting concentration of 386 
nM (1h) suffered an approximately 1.5-fold decrease at 6h (p<0.001) and an approximately 
2.5-fold decrease at 48h incubation (p<0.001), comparatively to 1h. In cells treated with 
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ADA (0.3 U/mL), concentration of ADO was 308 nM (1h), followed by an approximately 
4-fold decrease at 6h (p<0.001) and by an approximately 10-fold decrease at 48h 
incubation (p<0.001), when compared to 1h incubation. That ADO decrease was 
accompanied by an increase in INO levels in the extracellular space. Vehicle and ADA 
conditions presented significant increases in INO concentration, in a time-dependent 
manner (Figure 6B). An INO concentration of 91 nM was quantified on vehicle-treated 
cells, at 1h incubation, followed by significant increases of an approximately 1.1-fold at 6h 
(p<0.01) and by an approximately 3.5-fold at 48h (p<0.001). Results obtained with the 
medium collected from cells treated with ADA, showed significantly higher INO 
concentrations at all time points: after 1h incubation INO reached 142 nM, accompanied 
by an approximately 1.6-fold increase at 6h (p<0.001) and by an approximately 3-fold 
increase at 48h incubation (p<0.001). 
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Discussion 
ADO is a ubiquitous molecule formed in almost all cells and present at increased levels in 
the tumour microenvironment [8]. In fact, cancer cell growth may be affected by 
extracellular levels of ADO, the expression of different AR subtypes, and related signalling 
pathways activated [34, 35]. In the present work, we demonstrated that exogenous ADO 
concentrations of 0.1-100 μM caused increased proliferation on human C32 melanoma 
cells through AR activation (Figure 1A). These ADO concentrations, that mimic 
concentrations found within the tumour microenvironment, were already described to 
induce AR-dependent proliferation on colorectal carcinoma [29, 36] and glioma [37] cells. 
However, ADO at millimolar concentration caused C32 cell cytotoxicity through AR-
independent mechanisms (Figure 1A). Similar cytotoxic AR-independent effects were 
found in mouse N1E-115 neuroblastoma cells for millimolar concentrations of ADO [38]. 
This biphasic effect of exogenous ADO (proliferation vs. cytotoxicity) was also described 
in human colon [29] and epithelial [39] cancer cells. 
Moreover, we found that addition of pentostatin and ITU (ADA and AK inhibitors, 
respectively) enhanced proliferation of C32 cells, probably due to an increase in 
endogenous ADO levels (Figure 1B). This fact is in agreement with a previous report that 
described an increase in ADO levels in extracellular fluids of solid carcinomas after the 
addition of ADA and AK inhibitors, thus preventing the degradation of ADO into INO and 
the formation of AMP from ADO, respectively [40]. Currently, it is known that following 
ADO cellular release, or after its extracellular formation, ADO diffuses to the extracellular 
space where it binds and activates AR [41]. Consistent with this finding, we showed that it 
is fundamental for the proliferative effect observed that increased levels of endogenous 
ADO access the extracellular space in order to activate AR-dependent cell proliferation 
(Figure 1B). This fact was confirmed by i) addition of NBTI (ENTs inhibitor) prevented 
the increase of cellular proliferation by blocking increased levels of endogenous ADO 
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from being released into the extracellular space through NT and ii) pre-incubation of cells 
with CGS 15943 (non-selective AR antagonist) blocked ADO interactions with membrane 
AR (Figure 1B). 
Assuming that ADO promotes proliferation of cancer cells, and that AR signalling is 
controlled, at least in part, by extracellular levels of ADO, which are regulated by CD73 
and ADA [enzymes that produce and degrade ADO, respectively [35]], we have speculated 
that inhibiting production of ADO (using AOPCP, a CD73 inhibitor) or promoting its 
degradation (adding ADA) would block the proliferative effect of C32 cells. The relative 
importance of these two enzymes varies from cell to cell [42]. We found that addition of 
AOPCP significantly reduces cell proliferation (Figure 1B), suggesting that increased 
levels of AMP, in contrast to ADO, have an inhibitory effect on C32 cell proliferation. 
Similar results obtained with AOPCP were reported in glioma [43] and breast [44] cancer 
cells. We also found, after adding ADA, that the metabolic product of ecto-ADA, 
endogenous INO, was also able to significantly induce proliferation of C32 cells (Figure 
2). Although mainly cytosolic, ecto-ADA associated with CD26 (multifunctional cell 
membrane glycoprotein) also exists in cancer cells [45], but we added this enzyme since it 
has been reported that melanoma cells do not express extracellular CD26 [46], thus 
suggesting the lack of ecto-ADA activity in these cells. Previously, ADO (100 μM) and 
INO (300 μM) were reported to increase proliferation of rat kidney cells [47]. Thus, our 
subsequent studies were re-focused to characterize the proliferative effect of INO on C32 
melanoma cells. 
Approximately 430 nM (48h, Figure 6B) of endogenous INO (produced by the addition of 
ADA) induced significant C32 cell proliferation (Figure 2). Dipyridamole in a 
concentration reported to block all ENTs, thus preventing nucleoside uptake [38] did not 
alter cellular proliferation. Therefore, proliferation is induced by endogenous INO via 
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extracellular mechanisms. Moreover, pre-treated cells with CGS 15943 (non-selective AR 
antagonist) completely blocked the proliferative effect induced by the addition of ADA 
(Figure 2). The same effect was achieved when the selective A3AR antagonist (MRE 
3008F20) was used. Based on these facts, we suggest that the proliferation of C32 cells 
caused by increased levels of endogenous INO (ADA addition) is A3AR-mediated. 
Formerly, other studies reported that when metabolism of ADO is high, INO production is 
increased [48, 49]. Accordingly, we found nanomolar concentrations of ADO and INO 
(Figure 6) and while ADO levels decreased with time, INO levels increased in a time-
dependent manner. High basal levels of ADO could be justified by the presence of foetal 
bovine serum (FBS) in all conditions, including the vehicle, since a full composition of 
FBS is unknown and varies between batches [50]. In fact, FBS contains nucleotidase 
activity, even after serum inactivation [51], explaining the high levels of ADO found at 1h 
incubation in vehicle conditions. 
Results involving increased levels of ADA found in some cancer patients and malignancy 
could be linked to our results since we found proliferative effects caused by endogenous 
INO (Figure 2) and by addition of ADO (Figure 1A), suggesting a relevant role of the 
metabolic product of ADO in cancer. 
Micromolar concentrations of INO were previously described as being able to activate the 
A3AR [49]. Our findings are in agreement with this possibility as we found that stimulation 
of the A3AR, and not other AR subtypes, with 50 μM of INO can exert proliferative effects 
in our model system (Figure 3 and 5). Moreover, A3AR-responses induced by exogenous 
INO were higher than AR-responses induced by exogenous ADO (Figure 1A), in similar 
conditions. This fact could be justified, at least in part, by the removal of a possible 
inhibitory effect of ADO mediated by other AR subtypes that are insensitive to INO [48] 
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or by the fact that some modulatory actions of extracellular ADO are mediated by INO, 
after ADO uptake and conversion to INO [14], thus representing a delay on the final effect. 
Our results indicated a major role for cell-surface A3AR in the proliferative effects of 
exogenous INO, but the potential involvement of AR-independent (intracellular pathways) 
effects cannot be ruled out (Figure 3). We showed that CNTs could not mediate INO 
uptake since uridine (competing substrate for CNTs and ENTs) had an identical effect to 
that elicited by dipyridamole (ENTs inhibitor), both capable of nucleoside uptake 
inhibition [38], indicating that the proliferative effect is ENT-dependent (Figure 3). This 
fact was not observed for endogenous INO (Figure 2) perhaps because nanomolar 
concentrations of endogenous INO could only activate A3AR, contrary to micromolar 
concentrations that enter the cell besides the activation of A3AR. Although INO binds 
mainly to A3AR to promote its effects, there are studies reporting that INO uptake-
dependent mechanisms can also be involved [47, 52]. 
The selective P2Y1R antagonist (MRS 2500) was able to block the INO-induced 
proliferative effect, with an inhibition percentage similar to that caused by the ENT 
inhibitor (Figure 3). The most likely interpretation of this finding, proposed in Figure 7, is 
that after INO uptake, INO serves as an alternative source to produce ATP [53]. Then, cells 
release ATP [54] which activates plasma-membrane P2Y1 receptors and thereby modulates 
cellular function through specific signalling pathways [54, 55]. Expression of P2Y1R was 
reported in human melanomas [56] and activation of this P2Y subtype receptor by ATP 
was found to induce proliferation of retinal cells [57].  
Here in, we demonstrated that co-incubation of C32 cells with the selective A3AR and 
P2Y1R antagonists completely prevented the proliferative effect elicited by INO (Figure 3 
and 5). Moreover, the combination of these two antagonists, in the absence of added INO, 
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induced already a significant cytotoxicity in C32 cells, confirming the relevance of these 
two receptors in C32 cell survival (Figure 3 and 5). 
Efforts were also made in order to disclose the intracellular pathways sustained by 
exogenous INO on proliferation of C32 cells. To the best of our knowledge, we showed, 
for the first time, that INO affected cell proliferation through PLC-PKC-MEK1/2-ERK1/2 
and PI3K signalling pathways, the first being more relevant for C32 cell proliferation 
(Figure 4 and 7). A3AR are known to couple to G proteins, thereby inhibiting AC and 
activating PLC [34]. We propose that activation of A3AR by INO, in this melanoma cell 
line, is couple to activation of PLC-PKC-MEK1/2-ERK1/2 to enhance cell proliferation 
(Figure 7) since U73122, RO 32-0432, and U0126 (inhibitors of PLC, PKC, and MEK1/2, 
respectively) were able to similarly attenuate the proliferative effect induced by INO 
(Figure 4A) and the increasing ERK1/2 levels observed are completely dependent on 
MEK1/2 and A3AR activation (both completely block the effect), excluding the 
involvement of other pathways, namely PI3K, on rising ERK1/2 levels (Figure 4B). 
Suppression of PKC-MEK-ERK pathway was already described as a possible target to 
metastatic melanoma treatment, in mouse melanoma cells [58] and activation of A3AR is 
related to colon cancer cell proliferation through MEK-ERK [29]. 
We also found that PI3K activation was responsible for the remaining of C32 cell 
proliferation caused by INO (approximately 30%; Figure 4A) without ERK1/2 
involvement. We suggest that PI3K activation is mediated by indirect activation of P2Y1R 
(Figure 7). As such, the decrease on the INO-induced proliferation of both LY294002 and 
MRS 2500 are similar (Figure 3 and Figure 4A). Previously, stimulation of P2 receptors by 
ATP on human U138-MG glioma [59] and breast MCF-7 [60] cells were reported to cause 
cell proliferation mediated by PI3K. Activation of this pathway mediated by P2Y1R was 
also described in retinal cells proliferation [57]. 
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Accordingly, it seems that PLC-PKC-MEK-ERK and PI3K pathways are independent but 
both responsible for the final proliferative effect caused by exogenously added INO 
(Figure 7) since the combinations of U73122 (PLC inhibitor) with LY294002 (PI3K 
inhibitor) and U0126 (MEK1/2 inhibitor) with LY294002 (PI3K inhibitor) completely 
prevented C32 cell proliferation (Figure 4A). In fact, there was no cross-talk between ERK 
and PI3K pathways in proliferation of C6 glioma cells [61] and combined targeting of 
MEK and PI3K effector pathways was necessary to effectively inhibit NRAS mutant 
melanoma in vitro and in vivo [62]. Moreover, we observed that PLC-MAPK and PI3K 
pathways are important for C32 cell survival since the combinations tested, without INO, 
induced cell cytotoxicity (Figure 4A), corroborating the findings that MAPK and PI3K 
pathways are constitutively activated in most melanomas and these pathways are known to 
play critical roles on cell proliferation [2, 63]. 
In conclusion, we have demonstrated that INO causes proliferation of human C32 
melanoma cells through A3AR activation and an ENT-dependent mechanism, which seems 
to be related to indirect P2Y1R activation. PLC-PKC-MEK-ERK and PI3K activation are 
the signalling pathways responsible by INO-induced human C32 melanoma cell 
proliferation (Figure 7). According to our results, it would be reasonable to conclude that 
INO might have a significant role in melanoma cancer progression. Nevertheless, future 
studies using clinically relevant animal models are needed for a better understanding of 
these pathways in melanoma and what impact our discover can have on the cancer 
therapeutics. 
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Figure 1. Effects of ADO on human C32 melanoma cells. (A) Increasing concentrations 
of exogenous ADO (0.1–1000 µM), in the absence () or presence (■) of the AR 
antagonist, CGS 15943 (100 nM). DMSO (final concentration of 0.1% v/v) in DMEM-HG 
was used as vehicle. Results presented are means ± SEM, n=12 of 4 independent 
experiments. MTT reduction (% from vehicle) was evaluated at 48h incubation. Significant 
differences (One-Way ANOVA test, followed by the Student-Newman-Keuls post-hoc 
test): **p<0.01 vs. vehicle; ***p<0.001 vs. vehicle. (B) Cells treated with vehicle (DMSO 
in DMEM-HG, final concentration of 0.1% v/v), ADA inhibitor (pentostatin, 10 nM) and 
AK inhibitor (ITU, 100 nM), in the absence or presence of the bidirectional ENT inhibitor 
(NBTI, 10 µM) or the AR antagonist (CGS 15943, 100 nM). Cells were also treated with 
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the CD73 inhibitor (AOPCP, 100 µM). Results presented are means ± SEM, n=12 of 4 
independent experiments. MTT reduction (% from vehicle) was evaluated after 48h 
incubation. Significant differences (One-Way ANOVA test, followed by the Student-
Newman-Keuls post-hoc test): **p<0.01 vs. vehicle; ***p<0.001 vs. vehicle; ##p<0.01 vs. 
pentostatin; +++p<0.001 vs. (pentostatin + ITU). 
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Figure 2. Addition of exogenous ADA increased INO levels which caused human C32 
melanoma cells proliferation through A3AR activation. Cells were treated with ADA 
(0.3 U/mL) in the absence or presence of ENT inhibitor (dipyridamole, 10 µM), non-
selective AR antagonist (CGS 15943, 100 nM), and selective A3AR antagonist (MRE 
3008F20, 10 nM). DMSO (final concentration of 0.1% v/v) in DMEM-HG was used as 
vehicle. Results presented are means ± SEM, n=12 of 4 independent experiments. MTT 
reduction (% from vehicle) was evaluated at 48h incubation. Significant differences (One-
Way ANOVA test, followed by the Student-Newman-Keuls post-hoc test): ***p<0.001 vs. 
vehicle; ###p<0.001 vs. ADA. 
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Figure 3. Exogenous INO (50 and 100 µM) enhanced human C32 melanoma cells 
proliferation through A3AR direct activation and indirect P2Y1R activation triggered 
by an intracellular mechanism. For the lowest INO concentration (50 µM), cells were 
incubated in the absence or presence of selective A3AR antagonist (MRE 3008F20, 10 
nM), non-selective AR antagonist (CGS 15943, 100 nM), substrate for ENTs and CNTs 
(uridine, 300 µM), ENT inhibitor (dipyridamole, 10 µM), and selective P2Y1R antagonist 
(MRS 2500, 1 µM). DMSO (final concentration of 0.1% v/v) in DMEM-HG was used as 
vehicle. Results presented are means ± SEM, n=12 of 4 independent experiments. MTT 
reduction (% from vehicle) was evaluated at 48h incubation. Significant differences (One-
Way ANOVA test, followed by the Student-Newman-Keuls post-hoc test): *p<0.05 vs. 
vehicle; ***p<0.001 vs. vehicle; #p<0.05 vs. INO (50 µM); ###p<0.001 vs. INO (50 µM). 
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Figure 4. Simultaneous activation of PLC-PKC-MEK1/2-ERK1/2 and PI3K pathways 
induced by exogenous INO caused proliferation of human C32 melanoma cells. (A) 
Cells were treated with INO (50 µM), in the absence or presence of U-73122 (selective 
PLC inhibitor, 1 µM), U-73343 (PLC inactive analogue inhibitor, 1 µM), RO 32-0432 
(selective PKC inhibitor, 1 µM), U0126 (selective MEK1/2 inhibitor, 10 µM) and/or 
LY294002 (potent PI3K inhibitor, 1 µM). DMSO (final concentration of 0.1% v/v) in 
DMEM-HG was used as vehicle. Results presented are means ± SEM, n=12 of 4 
independent experiments. MTT reduction (% from vehicle) was evaluated at 48h 
incubation. Significant differences (One-Way ANOVA test, followed by the Student-
Newman-Keuls post-hoc test): *p<0.05 vs. vehicle; **p<0.01 vs. vehicle; ***p<0.001 vs. 
vehicle; ##p<0.01 vs. INO (50 µM); ###p<0.001 vs. INO (50 µM). (B) Increase of ERK1/2 
levels (OD450/ng of protein) on human C32 melanoma cells induced by INO, through 
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A3AR-MEK1/2 activation. Cells were treated with INO (50 µM) or ADA (0.3 U/mL), in 
the absence or presence of MRE 3008F20 (A3AR antagonist, 10 nM), U0126 (selective 
MEK1/2 inhibitor, 10 µM) or LY294002 (potent PI3K inhibitor, 1 µM) at 24h incubation. 
DMSO (final concentration of 0.1% v/v) in DMEM-HG was used as vehicle. Results 
presented are means ± SEM of 3-4 independent experiments. Significant differences (One-
Way ANOVA test, followed by the Student-Newman-Keuls post-hoc test): ***p<0.001 vs. 
vehicle; ###p<0.001 vs. INO; $$$p<0.001 vs. ADA. 
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Figure 5. BrdU incorporation (% from vehicle) evaluated at 48h incubation. Human 
C32 melanoma cells were treated with INO (50 µM) or ADA (0.3 U/mL), in the absence or 
presence of selective A3AR antagonist (MRE 3008F20, 10 nM), selective P2Y1R 
antagonist (MRS 2500, 1 µM) or selective MEK1/2 inhibitor (U0126, 10 µM). Results 
presented are means ± SEM, n=9‒12 of 3–4 independent experiments. Significant 
differences (One-Way ANOVA test, followed by the Student-Newman-Keuls post-hoc 
test): *p<0.05 vs. vehicle; ***p<0.001 vs. vehicle; +p<0.05 vs. INO (50 µM); +++p<0.001 
vs. INO (50 µM); ###p<0.001 vs. ADA. 
Experimental section 
75 
 
A
1h 6h 48h
0
100
200
300
400
***
###
***
###
++
+++
+++
Ex
tr
ac
el
lu
la
r c
on
ce
nt
ra
tio
n 
of
 A
D
O
 (n
M
)
B
1h 6h 48h
0
100
200
300
400
500
**
###
***
###
+++
+++
+
Ex
tr
ac
el
lu
la
r c
on
ce
nt
ra
tio
n 
of
 IN
O
 (n
M
)
Vehicle (0.1% v/v DMSO)
ADA (0.3 U/mL)
 
Figure 6. Extracellular concentrations of endogenous ADO and INO in human C32 
melanoma cells. Medium was collected from cells treated with vehicle (0.1% v/v of 
DMSO; black bars) or ADA (0.3 U/mL; grey bars), after 1, 6, and 48h incubation. Results 
presented are means ± SEM, n=12 of 4 independent experiments. (A) Extracellular 
concentration of ADO (nM) at 1, 6 and 48h incubation. Significant differences (One-Way 
ANOVA test, followed by the Student-Newman-Keuls post-hoc test): ***p<0.001 vs. 
vehicle (1h); ###p<0.001 vs. ADA (1h); ++p<0.01 vs. vehicle at same time point; +++p<0.001 
vs. vehicle at same time point. (B) Extracellular concentration of INO (nM) at 1h, 6h and 
48h incubation. Significant differences (One-Way ANOVA test, followed by the Student-
Newman-Keuls post-hoc test): **p<0.01 vs. vehicle (1h); ***p<0.001 vs. vehicle (1h); 
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###p<0.001 vs. ADA (1h); +p<0.05 vs. vehicle at same time point; +++p<0.001 vs. vehicle at 
same time point. 
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Figure 7. Proposed signalling pathways involved in proliferation of human C32 
melanoma cells caused by INO through direct A3AR activation and indirect P2Y1R 
activation. INO activates, primarily, PLC-PKC-MEK1/2-ERK1/2 pathway after binding to 
A3AR, causing cell proliferation. Simultaneously, INO can also enter into the cell through 
the ENT, being converted into ATP [(a) [50]] and release to the extracellular space [(b) 
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[51]]. Then, ATP activates PI3K, through the interaction with P2Y1R, contributing to cell 
proliferation. Red and purple boxes represent selective inhibitors and antagonists, 
respectively. Dashed arrows represent indirect pathways. 
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Abstract 
Purpose Metastatic melanoma is considered one of the most aggressive malignant tumours, representing the 
deadliest form of skin cancer. Melanoma progression is associated with the abrogation of normal controls 
that limit cell proliferation, migration and invasion, eventually leading to metastasis. Based on the variety of 
cellular mechanisms involved in metastatic progression, we aimed to evaluate the effect of inosine (50 μM) 
and the combination of Cl-IB-MECA (10 μM) with paclitaxel (10 ng/mL) on several stages of melanoma 
progression. 
Methods Proliferation, migration, adhesion, invasion, and colony formation were performed on human C32 
and A375 metastatic melanoma cells. Levels of ERK1/2 were also determined using an ELISA kit. 
Moreover, mouse aortic rings were treated with vascular endothelial growth factor, as to assess the 
microvessel sprouting (indicator of angiogenesis) in the presence of the referred compounds. 
Results We demonstrate that inosine induced, through A3 adenosine receptors activation, proliferation, 
migration, adhesion, and invasion on C32 and A375 melanoma cells, although with dissimilar importance on 
each melanoma cell line. Inosine also increased colony formation on A375 cells. Levels of ERK1/2 were 
increased after inosine exposure and were also dependent on A3 adenosine receptor activation in both cell 
lines. However, microvessel sprouting stimulated by inosine was not A3 adenosine receptor-dependent but 
was also prevented by the combination of Cl-IB-MECA with paclitaxel. 
Conclusions Cl-IB-MECA combined with paclitaxel was able to impair all the referred metastatic related 
mechanisms induced by inosine, making this approach a valuable tool for combination therapy against 
metastatic melanoma, overcoming paclitaxel common chemotherapeutic resistance. 
 
Keywords: melanoma, Cl-IB-MECA, paclitaxel, inosine, metastatic potential 
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Abbreviations 
AR: adenosine receptor 
BME: basement membrane extract 
BSA: bovine serum albumin 
Cl-IB-MECA: 2-chloro-N(6)-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide 
CTR: control 
DMSO: dimethyl sulfoxide 
DMEM-HG: dulbecco's modified eagle's medium-high glucose 
ECM: extracellular matrix 
ERK: extracellular signal-regulated kinase 
FBS: foetal bovine serum 
INO: inosine 
MAPK: mitogen-activated protein kinase 
MRE3008F20: N-[2-(2-furanyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N'-(4-
methoxyphenyl)urea 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
Opti-MEM: opti-minimal essential medium 
PBS: phosphate buffered saline 
PI3K: phosphatidylinositol 3-kinase 
PXT: paclitaxel 
ROS: reactive oxygen species 
VEGF: vascular endothelial growth factor 
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Introduction 
Metastatic melanoma is considered one of the most aggressive malignant tumours, representing the deadliest 
form of skin cancer (Bandarchi et al. 2010). This serious disease, derived from transformed epidermal 
melanocytes, has nowadays an alarming incidence increase (Jemal et al. 2010). The propensity of melanoma 
to metastasize results in early and general spread and, therefore, causing very high mortality rates (Bandarchi 
et al. 2010). Resistance to chemotherapy and radiotherapy (Bhatia et al. 2009) is the main reason for patients 
with metastatic melanoma to have an overall survival of less than two years (Bandarchi et al. 2010). 
Chemotherapeutic drugs, including dacarbazine, cisplatin, and paclitaxel (PXT), have been used, alone or in 
combination, although without significant survival rate improvement (Bhatia et al. 2009). Therefore, 
alternative treatment options are urgently needed since mechanisms that regulate tumour initiation and 
metastatic progression were not yet impaired at this present and effective therapies against them are still 
missing. Recently, we demonstrated that Cl-IB-MECA potentiates PXT cytotoxicity in human C32 and A375 
metastatic melanoma cells (Soares et al. 2013, 2014. Manuscript accepted for publication.), although the 
effect of this promising combination was not yet evaluated on the cellular mechanisms involved in melanoma 
progression. 
Cellular proliferation is fundamental for tumour metastasis, being crucial, therefore, the identification of key 
factors involved in the induction and progression of melanoma (Madonna et al. 2012). The activation of the 
intracellular mitogen-activated protein kinase (MAPK) and of phosphatidylinositol 3-kinase (PI3K) is 
involved in melanocyte proliferation (Haass and Herlyn 2005). Abrogation of normal control of these 
pathways drives melanocytes to become independent, causing uncontrolled cell proliferation and, ultimately, 
melanoma (Haass et al. 2005). The development of metastasis starts with cell migration from the primary 
tumour, followed by re-adhesion and tissue invasion, with complex interactions between tumour cells and 
their environment (Attoub et al. 2013). An increase or decrease in tumour cells adhesion to neighbouring 
cells, extracellular matrix (ECM), and endothelial cells, may occur at different stages of tumour progression 
(Huang et al. 1997), representing the degradation of ECM and basement membrane a critical step for tumour 
invasion and metastasis (Yamazoe et al. 2009). In addition, anchorage-independent growth (colony 
formation) is also important for malignant cell transformation as this ability increases the metastatic potential 
(Mori et al. 2009). Another important requirement for metastatic progression is the formation of new vessels 
(angiogenesis), which is induced by vascular endothelial growth factors (VEGF) released by tumour cells, as 
to ensure tumour growth/maintenance (Abdollahi and Folkman 2010). 
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Based on the variety of cellular mechanisms involved in metastatic progression, attempts should be made in 
order to find new effective drugs that might inhibit tumour cell proliferation, cell migration and/or invasion, 
and also drugs with anti-angiogenic properties. Adenosine is a well-known nucleoside that plays a key role 
on tumour growth and angiogenesis (Spychala 2000). Results from experimental tumour models showed that 
reducing extracellular levels of adenosine arrests tumour progression and prevents metastasis (Stagg et al. 
2011). Moreover, stimulation of A3 adenosine receptors (A3AR) has been reported to have growth-promoting 
as well as growth-inhibitory effects (Di Virgilio 2012). Previously, our group demonstrated a proliferative 
effect elicited by adenosine, which is even more notorious by its metabolic product, inosine (INO), on human 
C32 melanoma cells, through A3AR activation (Soares et al. 2014. Manuscript submitted for publication.). 
In the present study, we investigated whether INO promotes proliferation, migration, adhesion, invasion and 
colony formation, hallmarks of metastatic progression, on human C32 and A375 melanoma cells. The 
involvement of A3AR activation and of MAPK pathway was also examined on those effects. Furthermore, in 
the present work, the INO role on angiogenesis was also studied. The promising anti-cancer therapeutic 
combination of Cl-IB-MECA with PXT was used in order to evaluate its potential against the metastatic 
progression. 
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Materials and methods 
Chemicals 
All reagents used were of analytical grade. Cl-IB-MECA and MRE3008F20 were obtained from Tocris 
Bioscience (Bristol, United Kingdom). Cultrex® human basement membrane extract (BME) was purchased 
from Trevigen (Reagente 5, Porto, Portugal). Collagen type I and STAR ERK1/2 ELISA kit were purchased 
from Merk-Millipore (Interface, Amadora, Portugal). Foetal bovine serum (FBS), Glutamax, trypsin/EDTA, 
and opti-minimal essential medium (Opti-MEM®) were obtained from Invitrogen (Alfagene, Carcavelos, 
Portugal). Dulbecco's modified eagle's medium-high glucose (DMEM-HG), penicillin/streptomycin (10 000 
U/mL), INO, PXT, ECM gel, mouse VEGF, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT), bovine serum albumin (BSA), crystal violet solution, sodium citrate, dimethyl sulfoxide (DMSO), 
and all other chemicals were purchased from Sigma-Aldrich (Sigma-Aldrich-Química SA, Sintra, Portugal) 
of the highest purity available. 
 
Melanoma cell culture and treatment 
Human C32 and A375 metastatic melanoma cells obtained from ECACC – SIGMA (Sigma-Aldrich-Química 
SA, Sintra, Portugal) were used in this study. For cell culture maintenance, cells were seeded in complete 
medium [DMEM-HG medium with 10% (v/v) FBS, 1% (v/v) of a mixture of penicillin/streptomycin and 1% 
(v/v) Glutamax, pH 7.4], incubated at 37 ºC in a humidified atmosphere (95% air; 5% CO2) and sub-
cultivated twice a week. Cell passaging was done by trypsinization. All experiments were carried out with 
cells from batches with passage numbers lower than 50. 
Before each assay, cells were serum-starved for 4h, to allow synchronization of the cell cycle. Depending on 
the experiment goal, cells were treated with DMSO (maximum final concentration of 0.1% v/v; vehicle), 
INO (50 μM, INO50 (Soares et al. 2014), MRE3008F20 (selective A3AR antagonist ,10 nM (Soares et al. 
2013)), Cl-IB-MECA (10 μM, Cl10 (Soares et al. 2013)), PXT (10 ng/mL, PXT10 (Soares et al. 2013)), and 
combinations of these compounds (INO50+MRE3008F20, INO50+Cl50, INO50+PXT10, 
INO50+Cl10+PXT10, Cl10+PXT10), for different time-points. When MRE3008F20 was used, this 
compound was added 15 min prior to the addition of other compounds (Gessi et al. 2004). 
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MTT reduction assay 
Cells were seeded in 96-well plates with 200 μL per well of 8.0 × 104 cells/mL and 5.0 × 104 cells/mL, for 
C32 and A375 cells, respectively, and allowed to attach for 4h. Thereafter, cell medium was replaced by 
complete medium, in the absence or in the presence of compounds referred in section Melanoma cell culture 
and treatment, and cells incubated for different time-points, depending on the experiment goal. All 
conditions were performed in triplicate, initiated and processed in parallel. At the end of the incubation 
period, mitochondrial function was evaluated as an index of cell proliferation or cytotoxicity (Soares et al. 
2014), since mitochondrial dehydrogenases of living cells can reduce MTT to formazans (Mosmann 1983) 
being cells processed as described by our group (Soares et al. 2013). 
 
In vitro scratch assay 
The in vitro scratch assay was performed as described previously (Liang et al. 2007), with some 
modifications. Cells were seeded in 12-well plates with 1 mL per well of 3.5 × 105 cells and 3.0 × 105 cells, 
for C32 and A375 cells, respectively. After 4h for cell attachment at 37 ºC, scratches were carefully made 
across on full confluence of cell monolayers, using a 20 μL sterile pipette tip. Cells were then washed twice 
with warm phosphate buffered saline with calcium chloride and magnesium chloride (PBS) and incubated 
with complete medium, in the absence or in the presence of the compounds referred in section Melanoma cell 
culture and treatment, for 0, 12, and 24h incubation. All conditions were performed in duplicate, initiated 
and processed in parallel. At the bottom of each well, two arbitrary places were marked, where the width of 
the scratch was photographed using an Moticam 5 digital camera coupled to a Motic® AE200 inverted 
microscope (100X magnification; Spectra Services, VWR International, Carnaxide, Portugal). Scratch 
measurements were performed using the Motic® Images Plus 2.0 software. 
 
Cell adhesion assay 
The cell adhesion assay was performed as previously described (Chaturvedi et al. 2007), with some 
modifications. Plates of 96 wells were coated with 50 μL of ECM (12 mg/mL) or collagen (50 μg/mL), for 5 
min or 1h, respectively, at room temperature. Thereafter, coating was aspirated and plates were blocked with 
0.1% of BSA (w/v), for 30 min, at room temperature. C32 and A375 cells (100 μL per well of the suspension 
of 2.5 × 105 cells/mL) were prepared in complete medium, in the absence or in the presence of compounds 
referred in section Melanoma cell culture and treatment, and incubated for 1h. All conditions were 
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performed in triplicate, initiated and processed in parallel. At the end of the incubation period, cell 
suspension was discarded and wells were gently washed with warm PBS. Cells that adhered to the wells were 
incubated with MTT and processed as previously described (Soares et al. 2013). 
 
Cell invasion assay 
The cell invasion assay was performed as previously described (Chaturvedi et al. 2007), with some 
modifications. Corning-Transwell®-96 well supports with polyethylene terephthalate membranes (8.0 µm 
pores) were coated with 50 μL of BME (150 μg/mL) and incubated at 37 ºC, for 2h. Coating medium was 
then aspirated and supports blocked with 0.1% of BSA (w/v), for 30 min, at room temperature. Complete 
medium (150 μL) was then added to each reservoir well, with FBS as the chemo-attractant. C32 and A375 
cells were seeded in the upper chamber with 50 μL per well of a cell suspension prepared in serum-free 
medium (1.0 × 106 cells/mL), treated with the compounds referred in section Melanoma cell culture and 
treatment, and incubated for 3h. All conditions were performed in triplicate, initiated and processed in 
parallel. At the end of the incubation period, cell suspension and medium from the reservoir were aspirated. 
Each support was gently swabbed and washed with PBS. Cells that passed through and attached to the 
bottom of the membrane were incubated with MTT and processed as previously described (Soares et al. 
2013). 
 
Determination of ERK1/2 levels 
Cells were seeded in 6-well plates with 1 mL per well of 1.0 × 106 cells/mL and 2 mL of serum-free medium, 
and allowed to attach for 4h. Thereafter, cell medium was replaced by complete medium, in the absence or in 
the presence of the compounds referred in section Melanoma cell culture and treatment, and cells were 
incubated for 3h. All conditions were performed in duplicate, initiated and processed in parallel. At the end 
of incubation period, quantitative determination of ERK1/2 levels was done using the STAR ERK1/2 ELISA 
kit, according to the manufacturer’s instructions. 
 
Protein content determination 
Protein content of cellular fractions in total cell lysates for the ERK1/2 assay was determined using the Bio-
Rad RC DC protein assay kit, in accordance to the manufacturer’s instructions. Stock solutions of BSA were 
used as standards. 
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Colony formation assay 
The colony formation assay was performed as described previously (Taliaferro-Smith et al. 2009), with some 
modifications. Cells were plated in 6-well plates with 1 mL per well of 1 × 103 cells/mL and 2 mL of 
complete medium, in the absence or in the presence of the compounds referred in section Melanoma cell 
culture and treatment. After six days, medium was removed and colonies were washed with PBS. All 
conditions were performed in duplicate, initiated and processed in parallel. Colonies were fixed with 4% 
(w/v) paraformaldehyde in PBS (5 min), stained with 0.5% (v/v) crystal violet in distilled water (5 min), and 
rinsed with distilled water. Wells were photographed using a Sony Cyber-shot digital camera (10.1 Mega-
pixel) and a Motic® AE200 inverted microscope (40X magnification) coupled to a Moticam 5 digital camera 
(Spectra Services, VWR International, Carnaxide, Portugal). Colonies were manually counted. Afterward, 
crystal violet was eluted with sodium citrate in ethanol (0.1M) and absorbance at 540 nm was measured in an 
automated microplate reader (PowerWaveXS, Bio-Tek Instruments Inc, Vermont, USA). 
 
Animals 
Adult Swiss CD-1 mice (8-12 weeks old) were purchased to Charles River Laboratories (Barcelona, Spain). 
Throughout the experiments mice were maintained in plastic cages at 21 ± 2 ºC, on a 12h light/dark cycle 
with free access to food and water. Animal welfare and experimental procedures were performed in strict 
accordance with the care and use of laboratory animals and the related ethic regulations of our Faculty. All 
possible efforts were made to minimize the animals’ suffering and to reduce the number of animals used. 
 
Mouse aortic ring assay 
Animals were sacrificed by cervical dislocation and aorta was removed in a laminar flow hood. The mouse 
aortic ring assay was performed as described previously (Baker et al. 2012), with some modifications. After 
dissection, thoracic aorta was cleaned, cut into rings (approximately 0.5 mm in width) and placed into 96 
well-plates, containing 50 μL/well of collagen type I (1mg/mL), and then incubated at 37ºC, for 1h. The 
wells were then filled with150 μL of Opti-MEM® medium containing 2.5 % (v/v) FBS, 1% (v/v) of a mixture 
of penicillin/streptomycin, VEGF at a final concentration of 100 ng/mL (with 0.1% v/v DMSO) and the 
compounds referred in section Melanoma cell culture and treatment. At least six rings per condition were 
used in each experiment. On the ninth day, microvessel sprouting from each ring was examined using a 
Motic® AE200 inverted microscope (40X and 100X magnification) coupled to a Moticam 5 digital camera 
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(Spectra Services, VWR International, Carnaxide, Portugal). Microvessel sprouting areas were quantitative 
analysed with the ImageJ software. 
 
Statistical analysis 
Results are presented as mean ± SEM for n experiments performed. Statistical comparisons between groups, 
at the same time point, were performed with One-Way ANOVA, after Shapiro-Wilk test normality 
evaluation. Significance was accepted at p values <0.05. The Student–Newman–Keuls post hoc test was used 
once a significant p was achieved. Details of statistical analysis are found in the legend of each figure. 
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Results 
Cl-IB-MECA in combination with PXT decreased cell proliferation elicited by INO on both cell lines 
Human C32 and A375 melanoma cells were treated with 50 μM of INO (INO50), 10 nM of MRE3008F20, 
10 μM of Cl-IB-MECA (Cl10), 10 ng/mL of PXT (PXT10), and different combinations 
(INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, INO50+Cl10+PXT10, and Cl10+PXT10), for 1, 3 
and 24h (Fig. 1). Results from the MTT reduction assay showed that none of the compounds under study 
caused a significant effect on cell proliferation of C32 (Fig. 1A, 1C) and A375 cells (Fig. 1B, 1D), after 1 and 
3h incubation. However, after 24h, results showed that INO50 significantly increased proliferation of both 
cell lines, although more pronounced on C32 cells, in comparison to the effect caused by the same treatment 
on A375 cells (Fig. 1E, 1F). Moreover, this effect was partially prevented by MRE3008F20 (A3AR 
antagonist) in both cell lines (Fig. 1E, 1F). Treatment of C32 cells with Cl10+INO50 showed that Cl10 did 
not interfere with INO50-induced effect. In addition, Cl10 alone did not cause any change on MTT reduction 
of C32 cells at 24h (Fig. 1E). On the contrary, in A375, Cl10 was able to completely block MTT 
metabolization elicited by INO50. In fact, significant cytotoxicity was already observed for this compound 
alone, at the same incubation period (Fig. 1F). Results also revealed that when PXT10 was incubated with 
INO50, the effect elicited by INO50 was partially blocked in C32 (Fig. 1E) and completely prevented in 
A375 cells (Fig. 1F). Nevertheless, PXT10 alone caused similar cytotoxicity in both cell lines (Fig. 1E, 1F). 
Combination of INO50+Cl10+PXT10 and Cl10+PXT10 induced cytotoxicity on both melanoma cell lines, 
although more pronounced on A375 cells (Fig. 1E, 1F). 
 
MRE3008F20 and Cl-IB-MECA in combination with PXT impaired cell migration induced by INO 
with dissimilar importance on both melanoma cell lines 
Human C32 and A375 melanoma cells were treated with 50 μM of INO (INO50), 10 nM of MRE3008F20, 
10 μM of Cl-IB-MECA (Cl10), 10 ng/mL of PXT (PXT10), and different combinations 
(INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, INO50+Cl10+PXT10, and Cl10+PXT10) at 0, 12, 
and 24h. Cellular migration was investigated using the classic in vitro scratch assay in different time points, 
in both cell lines (Fig. 2 and Table 1). Results showed that INO50 significantly stimulated C32 and A375 
cells migration comparatively to vehicle (Fig. 2 and Table 1). Pre-treatment of cells with MRE3008F20 
revealed that this A3AR antagonist impaired the migration effects elicited by INO50, in both cell lines. 
However, this blocking effect was dissimilar for C32 and A375 cells, since in C32 cells migration stopped at 
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12h incubation, whereas in A375 cells, migration still increased, reaching values similar to vehicle cells at 
24h (Fig. 2A, 2B, Table 1). Nevertheless, MRE3008F20 by itself had no effect on C32 and A375 cell 
migration (Fig. 1C, 1D, Table 1). 
Results also indicate that Cl10 prevented the INO50-estimulated migration effect and also significantly 
hindered C32 cells from normal migration (Fig. 2A, Table 1). Cl10 was able to block A375 cell migration 
elicited by INO50, although this compound alone did not cause any effect on A375 cellular migration. 
PXT10 combined with INO50 or alone caused similar effects on C32 cells to those described for Cl10 (Fig. 
2A, Table 1). On the contrary, PXT10 was not able to prevent A375 cell migration caused by INO50 and, 
when incubated alone, this compound did not show any effect on A375 cell migration (Fig. 2B, Table 1). 
When C32 cells were treated with INO50+Cl10+PXT10, results indicate more pronounced effects on cells 
when compared to cells incubated with INO50+Cl10 or INO50+PXT10 (Fig. 2A, Table 1). However, 
INO50+Cl10+PXT10 only blocked A375 cell migration stimulated by INO50, whereas it did not 
significantly hinder cells from normal migration (Fig. 2B, Table 1). 
 
Melanoma cell adhesion induced by INO is A3AR and substrate dependent and the combination of Cl-
IB-MECA and PXT interferes with this effect 
Melanoma cells were treated with 50 μM of INO (INO50), 10 nM of MRE3008F20, 10 μM of Cl-IB-MECA 
(Cl10), 10 ng/mL of PXT (PXT10), and different combinations (INO50+MRE3008F20, INO50+Cl10, 
INO50+PXT10, INO50+Cl10+PXT10, and Cl10+PXT10), at 1h. The extracellular matrix, ECM gel (Fig. 3A 
and 3C), and collagen type I (not present in ECM; Fig. 3B and 3D) were used to evaluate the interference of 
these compounds on cellular adhesion. Results revealed that both cell lines show significant increased 
adhesion to both substrates, when compared to wells without any coating (Fig. 3A, 3B, 3C and 3D). C32 
cells treated with INO50 in the absence or in the presence of MRE3008F20 (A3AR antagonist), and placed in 
ECM gel, showed that INO50 did not statistically affect cell adhesion (Fig. 3A), although a positive tendency 
was observed. However, when these cells were placed in collagen type I, INO50 significantly stimulated cell 
adhesion and it seems that MRE3008F20 was able, at least in part, to prevent the INO50 effect (Fig. 3B). 
Similar effects elicited by INO50 alone, or in combination with MRE3008F20, were also found for A375 
cells, after 1h incubation (Fig. 3C and 3D). Nevertheless, MRE3008F20 by itself did not interfere with C32 
(Fig. 3A and 3B) and A375 (Fig. 3C and 3D) cell adhesion in both substrates, at 1h. 
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Cl10 significantly reduced C32 cell adhesion stimulated by INO50, in both matrices tested (Fig. 3A and 3B). 
Moreover, Cl10 alone impaired C32 cell adhesion when compared with vehicle with the respective substrate 
(Fig. 3A and 3B). Similar effects caused by Cl10 were also observed for A375 cells, at 1h (Fig. 3C and 3D). 
Results also showed that PXT10, in combination with INO or alone, did not cause any effect on cellular 
adhesion of both cell lines and in both substrates, at 1h (Fig. 3A, 3B, 3C, and 3D). However, when PXT10 is 
co-incubated with Cl10 in absence or in the presence of INO50, a significant reduction in cell adhesion, of 
both cell lines in ECM coated wells, was observed, comparatively to the respective vehicle condition (Fig. 
3A and 3B). Additionally, in ECM gel coated wells, C32 cells showed the highest decrease on cellular 
adhesion, for cells treated with the combination of Cl10+PXT10 (Fig. 3A). The same effect was not observed 
for A375 cells, since INO50+Cl10+PXT10 and Cl10+PXT10 had similar percentage inhibition for cellular 
adhesion (Fig. 3C). Melanoma C32 and A375 cells treated with INO50+Cl10+PXT10 or with Cl10+PXT10, 
placed on collagen type I (Fig. 3B and 3D), showed similar results to those obtained for ECM coated wells. 
 
Cell invasion is potentiated by INO50 through A3AR mechanisms, while Cl-IB-MECA with PXT 
causes different effects on cellular invasion in both melanoma cell lines 
Melanoma cells were treated with 50 μM of INO (INO50), 10 nM of MRE3008F20, 10 μM of Cl-IB-MECA 
(Cl10), 10 ng/mL of PXT (PXT10), and different combinations (INO50+MRE3008F20, INO50+Cl10, 
INO50+PXT10, INO50+Cl10+PXT10, and Cl10+PXT10), at 3h. Human BME coated inserts were used to 
assess whether these compounds, or their combination, affect cellular invasion, at 3h (Fig. 4). Results 
indicated that INO50 was able to significantly stimulate C32 cells invasion ability (Fig. 4A), being this effect 
even more pronounced in A375 cells incubated with INO50 (Fig. 4B). Moreover, it seems that the A3AR 
antagonist (MRE3008F20) was able to completely prevent this INO50 effect on C32 (Fig. 4A) whereas on 
A375 cells, MRE3008F20 was only able to partially block the increase of cell invasion elicited by INO50 
(Fig. 4B). Combination of INO50 with Cl10 showed that Cl10 significantly impaired INO-induced invasion 
in both cell lines (Fig. 4A and 4B). Furthermore, Cl10 alone already inhibited cellular invasion on both cell 
lines, although more significantly in A375 cells, when compared to respective vehicle cells (Fig. 4A and 4B). 
When PXT10 is co-incubated with INO50, no changes were observed in either cell line (Fig. 4A and 4B). 
Results also showed that C32 and A375 cells treated with PXT10 alone had no alteration on cell invasion, 
comparatively to vehicle (Fig. 4A and 4B). 
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C32 cells treated with INO50+Cl10+PXT10 had lower invasion levels indicating that Cl10+PXT10 caused 
significant reduction of cellular invasion stimulated by INO50 (Fig. 4A). Nevertheless, the use of the 
combination Cl10+PXT10 revealed the highest inhibitory effect on invasion on these cells (Fig. 4A). 
Significant reduction of cellular invasion was observed for A375 cells incubated with INO50+Cl10+PXT10 
(Fig. 4B), although this effect was inferior to that caused by INO50+Cl10. Similarly, Cl10 alone elicited a 
higher inhibitory cell invasion effect than that caused by Cl10+PXT10 alone (Fig. 4B). 
 
INO-dependent increase on ERK1/2 levels is A3AR-mediated and ERK1/2 levels are reduced by the 
combination of Cl-IB-MECA with PXT on melanoma cell lines 
Melanoma cells were treated with 50 μM of INO (INO50) in the absence or in the presence of MRE3008F20 
(10 nM), Cl-IB-MECA (10 μM, Cl10), PXT (10 ng/mL, PXT10), and Cl10+PXT10, for 3h incubation (Fig. 
5). Results obtained with the ERK1/2 ELISA kit revealed that INO50 significantly increased ERK1/2 levels 
on C32 cells (Fig. 5A) although this effect was more pronounced in A375 cells (Fig. 5B). Cells pre-incubated 
with MRE3008F20 showed that this A3AR antagonist was able to completely prevent the effect elicited by 
INO50, on both melanoma cells (Fig. 5). Results with Cl10 and INO50 indicated that this compound set the 
ERK1/2 levels comparable to vehicle levels, on C32 cells (Fig. 5A). For A375 cells, Cl10 besides 
suppressing the INO50-induced effect also decreased ERK1/2 levels to levels below values found in the 
vehicle (Fig. 5B). On the contrary, PXT10 proved to be ineffective on blocking the increase of ERK1/2 levels 
elicited by INO 50, on both cell lines (Fig. 5). The combination of INO50+Cl10+PXT10 showed that 
Cl10+PXT10 significantly reduced ERK1/2 levels induced by INO50, on C32 cells (Fig. 5A). Significant 
decrease in ERK1/2 levels was also observed for A375 cells incubated with INO50+Cl10+PXT10, although 
this effect was lower than what was caused by INO50+Cl10 (Fig. 5B). 
 
Anchorage-independent A375 cell growth was potentiated by INO50 through A3AR activation and is 
reduced by Cl-IB-MECA and PXT 
Melanoma cells were treated with 50 μM of INO (INO50), 10 nM of MRE3008F20, 10 μM of Cl-IB-MECA 
(Cl10), 10 ng/mL of PXT (PXT10), and different combinations (INO50+MRE3008F20, INO50+Cl10, 
INO50+PXT10, INO50+Cl10+PXT10, and Cl10+PXT10), for six days (Fig. 6). The ability of cancer cells to 
exhibit anchorage-independent cell growth was evaluated through the colony formation assay. Results 
showed that C32 melanoma cells have no colony-forming ability (data not shown). On the contrary, A375 
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cells not only had colony-forming ability as when treated with INO50 this ability was significantly increased 
(Fig. 6). Moreover, MRE3008F20 (A3AR antagonist) was able to completely prevent the INO50-colony 
stimulating effect (Fig. 6). When A375 cells were co-incubated with INO50 and Cl10, colony formation is 
significantly reduced (Fig. 6), being the size of these colonies smaller than those observed in vehicle 
condition (Fig. 6A). Similar effects were achieved by Cl10 alone (Fig. 6). Results also showed that PXT10 
alone or in combination with INO50 exhibited similar colony reduction ability (Fig. 6). PXT10 effects were 
more pronounced than those obtained with INO50+Cl10 or Cl10, although colonies size is, in average, larger 
than that present in all conditions with Cl10 (Fig. 6). The combination of INO50+Cl10+PXT10 showed that 
Cl10+PXT10 significantly reduced the increase ability of INO to increase colony formation (Fig. 6). 
 
Increased angiogenesis elicited by INO50 is reduced by the combination of Cl-IB-MECA and PXT 
Mouse aortic rings were treated with VEGF (100 ng/mL) in the absence or in the presence of 50 μM of INO 
(INO50), 10 nM of MRE3008F20, 10 μM of Cl-IB-MECA (Cl10), 10 ng/mL of PXT (PXT10), and different 
combinations (INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, INO50+Cl10+PXT10, and 
Cl10+PXT10), for nine days, to assess angiogenesis in vitro (Fig. 7). Rings without VEGF were used as 
negative controls for microvessel sprouting. Results showed that INO50 is an important angiogenesis 
promotor since it significantly stimulated microvessel sprouting, when compared to VEGF alone (Fig. 7). 
However, this effect was not prevented by the A3AR antagonist (MRE3008F20). Additionally, MRE3008F20 
alone did not interfere with VEGF-induced sprouting (Fig. 7). Rings treated with Cl10 showed that this 
compound completely inhibited INO50-induced effect and microvessel sprouting was even lower than VEGF 
levels (Fig. 7). A similar effect was observed for Cl10 incubated alone. Results also revealed that PXT10 did 
not cause any effect on microvessel sprouting elicited by INO50 or VEGF (Fig. 7). Nevertheless, when 
PXT10 was combined with Cl10, significant reduction on microvessel sprouting induced by INO50 was 
observed, representing the best combination for blocking INO50 effects (Fig. 7). Additionally, the 
combination of Cl10 with PXT10 almost totally abrogated VEGF-induced microvessel sprouting.
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Discussion 
Melanoma progression is associated with the abrogation of the normal controls that limit cell migration and 
invasion, eventually leading to metastasis (Haass and Herlyn 2005). Patients with metastatic melanoma have 
low survival rates due to the high resistance to chemotherapy and radiotherapy (Bhatia et al. 2009). We 
previously showed that the combination of Cl-IB-MECA with PXT caused cytotoxicity, through different 
mechanisms, on human C32 and A375 melanoma cells, at clinically relevant concentrations (Soares et al. 
2013, 2014b). 
Results now presented are the first demonstration that Cl-IB-MECA (10 μM), alone or in combination with 
PXT (10 ng/mL), is also very efficient in preventing the metastatic process stimulated by INO (50 μM) on 
human melanoma cells by (i) inhibiting cell proliferation; (ii) stopping cell migration; (iii) preventing ECM 
and collagen cell adhesion; (iv) blocking BME cell invasion through the reduction of ERK1/2 levels; (v) 
diminishing colony formation ability; and (vi) reducing angiogenesis (Fig. 8). Moreover, we provided 
evidence that the effects enhanced by INO on cells are A3AR-dependent, but the pro-angiogenesis effect is 
A3AR-independent. Nevertheless, Cl-IB-MECA+PXT was able to abolish all of them, although with 
dissimilar importance on human C32 and A375 melanoma cells, and almost always more efficiently than the 
compounds by themselves. 
Before beginning of the studies on the metastatic potential of INO and the effects of the combination Cl-IB-
MECA+PXT, the MTT reduction assay was performed to evaluate cellular proliferation or cytotoxicity at the 
same time points of migration, adhesion, and invasion assays, in both cell lines, as to avoid confounding 
effects on the assessment of the metastatic potential. We observed that in the time points of adhesion and 
invasion (1 and 3h) no changes were seen, thus increasing the reliability to our data, instead of being 
attributed to the overall proliferation induced by INO. At 24h, a significant increase in INO proliferation of 
both cell lines was observed. The only assay performed at this time point was migration where, in fact, the 
proliferation ability of INO can contribute to the migration stimulating effect. The data obtained on MTT and 
migration is, therefore, complementary. Cellular proliferation and migration are essential to several functions, 
such as melanoma tumour metastasis (Haass et al. 2005). Results of the in vitro scratch assay demonstrate 
that although the proliferation elicited by INO is only partially mediated by A3AR activation at 24h, 
migration caused by this nucleoside is totally A3AR-dependent, on both melanoma cell lines, after 24h 
incubation. This fact is not surprisingly since we have previously described that INO and adenosine induced 
C32 melanoma cell proliferation through A3AR activation, after 48h (Soares et al. 2014a), although INO is 
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considered only an A3AR partial agonist (Jin et al. 1997). Nevertheless, activation of A2BAR by adenosine is 
reported to increase breast tumour cell migration in vitro (Stagg et al. 2010). This difference in AR activation 
could be related, at least in part, to the different cellular models used, reinforcing the fact that AR activation 
depends on cell type or concentration used (Di Virgilio 2012), even when similar results are observed. 
Interestingly, Cl-IB-MECA at our working concentration (10 µM) did not cause any cytotoxic effect on C32 
cells, after 24h, while it significantly decreased C32 cell migration elicited by INO or even by vehicle. On the 
contrary, Cl-IB-MECA alone already induced A375 cytotoxicity at 24h, while it did not cause significant 
interference in cell migration when compared to vehicle. Specific activation of A3AR by Cl-IB-MECA was 
already described to reduce proliferation on A375 cells (Merighi et al. 2002). Moreover, in our data, Cl-IB-
MECA blocked the stimulated migration effect elicited by INO. Although we have previously demonstrated 
that micromolar concentrations of Cl-IB-MECA cause melanoma C32 cell cytotoxicity through AR-
independent mechanisms (Soares et al. 2013), herein we may assume that Cl-IB-MECA prevents cellular 
migration through interaction with A3AR. In fact, Cl-IB-MECA (at micromolar concentrations) was 
described as a silent antagonist to A3AR in the presence of micromolar concentrations of adenosine and INO 
(Wolber and Fozard 2005). However, it is well established that A3AR agonists lose their selectivity at high 
concentrations (Mlejnek et al. 2013), which indicate that Cl-IB-MECA could also mediate its effects by 
interaction with other AR subtypes, in our model. 
Discrepancies between C32 and A375 cells concerning their susceptibility to Cl-IB-MECA were previously 
described by us (Soares et al. 2014b). This fact may be justified by the different gender cell donator, as C32 
were collected from male and A375 from female and different metastatic patterns were already found on 
female and male melanoma patients (Mervic 2012). Results obtained with PXT also differ between C32 and 
A375 cells, regarding its anti-migratory effects. Although in both melanoma cell lines, PXT similarly caused 
cytotoxicity at 24h, this drug only stopped C32 cell migration when compared to vehicle and INO conditions, 
without significantly affecting A375 cell migration. The classical anti-cancer PXT mechanism is the mitotic 
spindle stabilization, leading to inhibition of cell proliferation (Ahmed et al. 2011). However, PXT might 
exert some anti-cancer properties through mechanisms other than its well-known anti-mitotic activity (Tran 
et al. 2009). In fact, we previously reported that PXT also leads to the generation of reactive oxygen species 
(ROS) on C32 melanoma cells (Soares et al. 2013). B16F10 mouse melanoma cell migration and growth was 
described to be controlled by ROS production (Im et al. 2012). Taken together, these overall mechanisms 
may possible explain the anti-migratory effect of PXT on C32 cells. 
Experimental section 
132 
 
When C32 and A375 cells were treated with Cl-IB-MECA+PXT, results demonstrated that this combination 
caused severe cytotoxicity and blocked INO induced proliferating effects, being these toxic effects more 
pronounced on A375 cells, after 24h. Moreover, this combination revealed to be more efficient in blocking 
INO-dependent migration effect on C32 cells, whereas Cl-IB-MECA+PXT elicited similar anti-migration 
effects on A375 cells to those caused by Cl-IB-MECA alone. Therefore, Cl-IB-MECA+PXT combination is 
very efficient in preventing A375 cell proliferation, but PXT, alone or in combination, does not contribute for 
stopping A375 cell migration. This observation is not surprising, since we found that PXT caused ROS 
generation on A375 cells (Soares et al. 2014b) and ROS production triggered by chemotherapeutic agents 
may promote cell damage and cell death, but can also lead to oncogenic phenotype of cancer cells (ROS are 
secondary messengers in intracellular signalling pathways) (Fruehauf and Meyskens 2007). 
We found that both melanoma cell lines significantly adhere to ECM and collagen type I, after 1h incubation, 
which is in agreement with a study where SK-MEL-28 melanoma cells also strongly adhere to ECM and 
collagen type I and IV (Ohkawa et al. 2010). Although INO is considered an A3AR partial agonist (Jin et al. 
1997), we demonstrated that INO significantly stimulated cell adhesion to collagen type I, through A3AR-
dependent mechanisms. Increased levels of extracellular adenosine were also reported to increase adhesion of 
several melanoma cell lines (Sadej et al. 2006). 
We also showed that Cl-IB-MECA has anti-adhesion properties on C32 and A375 cells, and in both adhesion 
matrices (ECM and collagen type I). The fact that other AR subtypes than A3AR might be involved is a 
possibility, since at micromolar concentrations, agonists lose their selectivity (Mlejnek et al. 2013), and Cl-
IB-MECA action as a silent antagonist may justify, again, the prevention INO-stimulatory effect on cell 
adhesion. On the contrary, PXT did not interfere with melanoma cellular adhesion. Nevertheless, PXT was 
described to inhibit the adhesion of B16F10 mouse melanoma cells to fibronectin and laminin (Wang et al. 
2003), suggesting that human melanoma cells are more resistant to PXT treatments than mouse melanoma 
cells, concerning cell adhesion. In fact, human melanoma cells have been reported to present high adhesion 
ability, becoming very resistant to chemotherapy (Locatelli et al. 2009). 
The combination Cl-IB-MECA+PXT promoted anti-adhesion effects, similar to those caused by Cl-IB-
MECA alone, suggesting that in the combination Cl-IB-MECA+PXT, only Cl-IB-MECA is responsible for 
preventing cell adhesion. 
Melanoma cell invasion was also studied, using human BME (also designated by matrigel), widely used on 
in vitro tumour cell invasion assays (Sallam et al. 2010). We found that INO significantly enhanced the 
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destruction of the first barrier on the cell invasion process, the basement membrane, being the invasive ability 
found for A375 cells higher. Moreover, this INO effect was A3AR-dependent in both melanoma cell lines. 
Results demonstrated that Cl-IB-MECA prevented the invasion observed with vehicle and INO, without 
causing cytotoxicity, at 3h incubation. Moreover, PXT did not exhibit any anti-invasion ability on C32 and 
A375 cells, at 3h, in agreement to the adhesion assay results. However, reduction of cell invasiveness was 
observed in cell breast cancer cells for PXT concentrations also with no effect on cell viability (Tran et al. 
2009). Results also suggested that the anti-invasive ability of the combination Cl-IB-MECA+PXT is only due 
to Cl-IB-MECA, as similar effects to those caused by Cl-IB-MECA alone were observed. We believe that Cl-
IB-MECA blocked the stimulatory effect of INO (Jin et al. 1997), suggesting again the possibility of Cl-IB-
MECA behaves as a silent A3AR antagonist (Wolber and Fozard 2005). 
To the best of our knowledge, it is the first time that Cl-IB-MECA is reported to cause anti-migration, anti-
adhesion, and anti-invasion effects on human melanoma cells, and this can, at least in part, explain the 
positive results in clinical assays with hepatocellular carcinoma patients (Stemmer et al. 2013). 
Detection of ERK1/2 levels, at the same time incubation of the invasion assay, seems to indicate that the 
expression of this protein is significantly increased by INO through A3AR-dependent activation, on both 
melanoma cell lines. Higher levels of ERK1/2 were found on A375 cells, which is the cell line with higher 
invasion ability. Adenosine 100 μM was also found to stimulate ERK1/2 activation on A375 cells (Merighi et 
al. 2002). Cl-IB-MECA blocked the INO effect, and PXT did not cause any effect on ERK1/2 level, on both 
C32 and A375 cells, in agreement with the invasion assay results. Time-course studies have been published 
with Cl-IB-MECA and A375: 10 μM of Cl-IB-MECA was shown to had no effect on the expression level of 
ERK1/2 on A375 cells, at 1h incubation (Merighi et al. 2002), but years later other study stated that Cl-IB-
MECA, in the same melanoma model, reduced basal levels of ERK1/2 in a 2h incubation period, by A3AR 
activation, which in turn inhibited cell proliferation (Merighi et al. 2005). An adaptation process therefore 
occurs with Cl-IB-MECA incubation and, overall, we suggest that regulation of ERK1/2, one of the end 
proteins of the MAPK signalling pathway, is probably involved on adhesion and/or invasion processes 
induced by INO. Accordingly, adhesion-dependent ERK1/2 cascade activation was also found in human SK-
MEL-24 and SK-MEL28 melanoma cells (Conner et al. 2003). Moreover, targeting ERK1/2 was also 
described as an efficient strategy to reduce B164A5 melanoma cell invasion (Romanchikova et al. 2013), as 
we observed for Cl-IB-MECA. 
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The ability to exhibit anchorage-independent cell growth (colony-forming ability) was also evaluated since it 
has been linked to the tumour’s metastatic potential (Mori et al. 2009). We found that C32 cells did not form 
colonies, while A375 cells exhibited anchorage-independent cell growth. This fact may indicate that the 
aggressiveness of A375 cells is higher than C32 cells, thus suggesting higher metastatic potential for A375 
cells. Moreover, the colony formation of these cells was enhanced by INO through A3AR activation. The fact 
that Cl-IB-MECA decreased the size of the colonies, contrary to PXT that decreased the overall colony 
number, suggests that although both compounds combined are capable of diminishing vehicle and INO-
induced colony formation, through different pathways, therefore enhancing the full potential of the 
combination. Similar approach was reported for the related Cl-IB-MECA compound, IB-MECA, which was 
reported to improve the chemotherapeutic effect of 5-fluorouracil, inhibiting colony formation of HCT-16 
colon carcinoma cells, through downregulation of AKT and NF-kappaB protein expression (Bar-Yehuda et 
al. 2005). Previously, contrary effects induced by Cl-IB-MECA (10 μM) to those reported by us, described 
Cl-IB-MECA as to promote cell survival, increasing the number of colonies on A375 cells (Merighi et al. 
2002). 
Tumour cell survival and growth are dependent of adequate nutrient supply by blood. Thus, when cells are 
distant from blood vessels, expansion of tumour mass depends on angiogenesis (Sung et al. 2007). Our data 
indicate that INO significantly enhanced microvessel sprouting through A3AR-independent mechanisms, and 
Cl-IB-MECA was able to prevent not only the INO-induced sprouting effect but also the normal vessel 
sprouting elicited by VEGF. Although Cl-IB-MECA was never reported to cause anti-sprouting effects, thio-
Cl-IB-MECA, a related Cl-IB-MECA compound has been recently reported to decrease microvessel 
sprouting in mouse aortic rings through downregulation of PI3K/AKT/mTOR and ERK signalling of 
endothelial cells (Kim et al. 2013). In addition, we previously reported that Cl-IB-MECA decreases mTOR 
levels in melanoma cells (Soares et al. 2014b), suggesting that mTOR could represent a possible pathway by 
which Cl-IB-MECA mediates this observed anti-angiogenic effect. We demonstrated that although PXT 
alone did not prevent the development of microvessels promoted by INO, Cl-IB-MECA+PXT was the mostly 
effective condition in blocking microvessel sprouting. 
In summary, we characterized, for the first time, the metastatic potential of two human melanoma cell lines, 
C32 and A375, and demonstrated that INO functions as an aggressiveness enhancer for both cells. We also 
provided evidence that, although some effects are prevented by using the selective A3AR antagonist, 
MRE3008F20, the combination Cl-IB-MECA+PXT revealed to be almost always more efficient in stopping 
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metastatic progression. Moreover, the mechanisms not impaired by the clinically used PXT in melanoma are 
stopped upon Cl-IB-MECA addition. Therefore, we propose this combination as a new therapeutic approach 
for metastatic melanoma since it not only increases cytotoxicity but also inhibits metastatic progression, by 
affecting several mechanisms, namely migration, adhesion, invasion and angiogenesis (Fig. 8), overcoming 
PXT common chemotherapeutic resistance. 
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Figure captions 
 
Fig.1 MTT reduction (% from vehicle) assay, after 1h (A, B), 3h (C, D), and 24h (E, F). Human C32 (A, C, 
and E) and A375 (B, D, and F) melanoma cells treated with INO (50 µM; INO50), MRE3008F20 (10 nM), 
Cl-IB-MECA (10 μM; Cl10), PXT (10 ng/mL; PXT10), and different combinations (INO50+MRE3008F20, 
INO50+Cl10, INO50+PXT10, INO50+Cl10+PXT10, and Cl10+PXT10). DMSO (final concentration of 
0.1% v/v) in DMEM-HG was used as vehicle. Results are presented as means ± SEM, n=9-12 of 3-4 
independent experiments. Significant differences (One-Way ANOVA test, followed by the Student-Newman-
Keuls post-hoc test): *p<0.05 vs. vehicle; **p<0.01 vs. vehicle; ***p<0.001 vs. vehicle; #p<0.05 vs. INO50; 
###p<0.001 vs. INO50; $p<0.05 vs. corresponding condition without INO50; $$$p<0.001 vs. corresponding 
condition without INO50 
 
Fig.2 Melanoma cell migration elicited by INO50 is A3AR-mediated and impaired by Cl-IB-MECA in 
combination with PXT. Human C32 and A375 melanoma cells treated with INO (50 µM; INO50), 
MRE3008F20 (10 nM), Cl-IB-MECA (10 μM; Cl10), PXT (10 ng/mL; PXT10), and different 
(INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, INO50+Cl10+PXT10, and Cl10+PXT10). DMSO 
(final concentration of 0.1% v/v) in DMEM-HG was used as vehicle. Representative photographs of 
melanoma cell migration of C32 cells (A) and A375 cells (B) of n=8 (4 independent experiments), after 0, 
12, and 24h incubation. Black lines and dashed lines indicate the final and the initial scratched edges, 
respectively. Scale bar, 200 μm 
 
Fig.3 Melanoma cell adhesion on ECM gel and collagen type I. Human C32 and A375 melanoma cells 
treated with INO (50 µM; INO50), MRE3008F20 (10 nM), Cl-IB-MECA (10 μM; Cl10), PXT (10 ng/mL; 
PXT10), and different combinations (INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, 
INO50+Cl10+PXT10, and Cl10+PXT10). DMSO (final concentration of 0.1% v/v) in DMEM-HG was used 
as vehicle. Results of cell adhesion on ECM gel (% from vehicle) of C32 (A) and A375 (C) cells are 
presented as means ± SEM, n=9 of 3 independent experiments, after 1h incubation. Significant differences 
(One-Way ANOVA test, followed by the Student-Newman-Keuls post-hoc test): ***p<0.001 vs. vehicle; 
###p<0.001 vs. INO50; $p<0.05 vs. corresponding condition without INO50. Results of cell adhesion on 
collagen type I (% from vehicle) of C32 (B) and A375 (D) cells are presented as means ± SEM, n=9 of 3 
independent experiments, after 1h incubation. Significant differences (One-Way ANOVA test, followed by 
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the Student-Newman-Keuls post-hoc test): *p<0.05 vs. vehicle; **p<0.01 vs. vehicle; ***p<0.001 vs. 
vehicle; ###p<0.001 vs. INO50; $$p<0.01 vs. corresponding condition without INO50; $$$p<0.001 vs. 
corresponding condition without INO50 
 
Fig.4 Melanoma cell invasion on BME. Human C32 and A375 melanoma cells treated with INO (50 µM; 
INO50), MRE3008F20 (10 nM), Cl-IB-MECA (10 μM; Cl10), PXT (10 ng/mL; PXT10), and different 
combinations (INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, INO50+Cl10+PXT10, and 
Cl10+PXT10). DMSO (final concentration of 0.1% v/v) in DMEM-HG was used as vehicle. Results of cell 
invasion on BME (% from vehicle) of C32 (A) and A375 (B) cells are presented as means ± SEM, n=9 of 3 
independent experiments, after 3h incubation. Significant differences (One-Way ANOVA test, followed by 
the Student-Newman-Keuls post-hoc test): *p<0.05 vs. vehicle; **p<0.01 vs. vehicle; ***p<0.001 vs. 
vehicle; #p<0.05 vs. INO50; ##p<0.01 vs. INO50; ###p<0.001 vs. INO50; $p<0.05 vs. corresponding condition 
without INO50; $$p<0.01 vs. corresponding condition without INO50 
 
Fig.5 Levels of ERK1/2 on human C32 (A) and A375 (B) melanoma cells treated with INO (50 µM; INO50), 
INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, and INO50+Cl10+PXT10, after 3h incubation. 
DMSO (final concentration of 0.1% v/v) in DMEM-HG was used as vehicle. Results of ERK1/2 levels 
(OD450/ng protein) are presented as means ± SEM of 3 independent experiments. Significant differences 
(One-Way ANOVA test, followed by the Student-Newman-Keuls post-hoc test): *p<0.05 vs. vehicle; 
#p<0.05 vs. INO50; ##p<0.01 vs. INO50; ###p<0.001 vs. INO50 
 
Fig.6 Colony formation assay of human A375 melanoma cells treated with INO (50 µM; INO50), 
MRE3008F20 (10 nM), Cl-IB-MECA (10 μM; Cl10), PXT (10 ng/mL; PXT10), and different combinations 
(INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, INO50+Cl10+PXT10, and Cl10+PXT10), after six 
days. DMSO (final concentration of 0.1% v/v) in DMEM-HG was used as vehicle. (A) Images from colonies 
stained with crystal violet were obtained with a digital camera (I) or with a microscope coupled to a digital 
camera [in this case with magnification of 40x (II)]. Scale bar, 500 μm. (B) Results of the number of colonies 
per well are means ± SEM of n=8, 4 independent experiments. Significant differences (One-Way ANOVA 
test, followed by the Student-Newman-Keuls post-hoc test): **p<0.01 vs. vehicle; ***p<0.001 vs. vehicle; 
##p<0.01 vs. INO50; ###p<0.001 vs. INO50; $$$p<0.001 vs. corresponding condition without INO50. (C) 
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Results of optical density (540 nm) are means ± SEM of n=8, 4 independent experiments. Significant 
differences (One-Way ANOVA test, followed by the Student-Newman-Keuls post-hoc test): *p<0.05 vs. 
vehicle; ***p<0.001 vs. vehicle; #p<0.05 vs. INO50; ###p<0.001 vs. INO50 
 
Fig.7 Mouse aortic rings treated with VEGF (100 ng/mL with 0.1% v/v DMSO) in the absence or in the 
presence of INO (50 µM; INO50), MRE3008F20 (10 nM), Cl-IB-MECA (10 μM; Cl10), PXT (10 ng/mL; 
PXT10), and different combinations (INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, 
INO50+Cl10+PXT10, and Cl10+PXT10), after nine days. (A) Images presented were obtained with a 
microscope coupled to a digital camera, magnification of 40x (I; scale bar, 500 μm) and 100x (II; scale bar, 
200 μm). (B) Results of relative microvessel sprouting areas (% from VEGF) are presented as means ± SEM 
of n=3-5 independent experiments. Significant differences (One-Way ANOVA test, followed by the Student-
Newman-Keuls post-hoc test): ***p<0.001 vs. vehicle; ###p<0.001 vs. INO50; $$$p<0.001 vs. corresponding 
condition without INO50 
 
Fig.8 Illustration representing enhanced proliferation, migration, adhesion, invasion, and increase on ERK1/2 
levels stimulated by inosine on human C32 and A375 melanoma cells through A3AR activation. Inosine also 
increases the ability of A375 cells to form colonies which is mediated by A3AR. INO induces microvessel 
sprouting through A3AR independent mechanisms. These pathways involved in melanoma progression are 
drastically decreased by the combination of Cl-IB-MECA with PXT 
 
Table.1 Quantification of scratch closure (% from initial scratched edges) after cell treatment with INO (50 
µM; INO50), MRE3008F20 (10 nM), Cl-IB-MECA (10 μM; Cl10), PXT (10 ng/mL; PXT10), and different 
combinations of these compounds (INO50+MRE3008F20, INO50+Cl10, INO50+PXT10, 
INO50+Cl10+PXT10, and Cl10+PXT10), at 12 and 24h incubation. DMSO (final concentration of 0.1% v/v) 
in DMEM-HG was used as vehicle. Results presented are means ± SEM, n=8 of 4 independent experiments. 
Significant differences (One-Way ANOVA test, followed by the Student-Newman-Keuls post-hoc test): 
*p<0.05 vs. vehicle; **p<0.01 vs. vehicle; ***p<0.001 vs. vehicle; #p<0.05 vs. INO50; ###p<0.001 vs. 
INO50; $p<0.05 vs. corresponding condition without INO50; $$p<0.01 vs. corresponding condition without 
INO50; $$$p<0.001 vs. corresponding condition without INO50 
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Fig.4 
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TABLE 1 Quantification of scratch closure (% from initial scratched edges) after cell treatment, at 12 and 
24h incubation. 
 
 
Scratch closure 
(% from initial scratched edges) 
(mean ± SEM) 
C32 cells A375 cells 
12h 24h 12h 24h 
Vehicle 56±2 89±4 68±3 75±4 
INO50 67±1*** 99±3* 62±1 99±2* 
INO50+MRE3008F20 50±3### 54±1***;###;$$$ 64±2 76±3# 
MRE3008F20 55±2 83±2 64±4 74±5 
INO50+Cl10 28±1***;### 61±4***;### 62±1$$$ 75±2# 
Cl10 33±2*** 60±4*** 31±4*** 68±6 
INO50+PXT10 32±3***;### 62±2***;### 62±3 98±8*;$ 
PXT10 34±1*** 56±4*** 61±4 75±7 
INO+Cl10+PXT10 38±3***;###;$$$ 44±1***;###;$$ 49±7**;# 76±7# 
Cl10+PXT10 22±1*** 32±2*** 49±8** 61±6 
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	 1. GENERAL DISCUSSION 
 
 Data highlight the role of ADO as a crucial regulatory autocrine and paracrine 
factor that accumulates in the tumour microenvironment [124], favouring the neoplastic 
process [125]. The concentration of this nucleoside can rapidly increase in response to 
pathophysiological conditions, making it possible to activate AR, generating various 
cellular responses [126]. 
 The overall aim of this thesis was to explore the role of the ADO-AR system in the 
complex interplay of proliferation, death and metastatic progression of melanoma cells 
and, if possible, find new therapeutic approaches for this deadliest form of skin cancer. To 
accomplish this goal human C32 [127], A375 [128] and K1735-M2 [129] melanoma cells 
were selected as these are well-accepted models to evaluate cytotoxic compounds that can 
be of interest against melanoma. The choice of these amelanotic cells is related to the fact 
that dedifferentiation is often associated with higher ability for cell proliferation [130]. 
 Results showed, for the first time, the expression of all subtypes of AR (A1, A2A, A2B 
and A3) on human C32 and mouse K1735-M2 melanoma cells, by immunocytochemistry, 
and confirm their presence on human A375 melanoma cell line [131]. The A3AR seems to 
be poorly expressed in all cell lines [131], which is in agreement with previous work 
showing that A3 mRNAs are less abundant then A2A and A2B mRNAs in human A375 
melanoma cells [109]. Moreover, although melanoma and other tumours express high 
levels of A3AR [108], this fact is not true for all types of cancer cells, as human MCF-7 
breast cancer cells have undetectable AR expression, whereas human MDA-MB-231 breast 
cancer cells only express high levels of A2BAR [132]. 
 Pharmacological characterization showed that activation of A1AR, A2AAR, and 
A3AR at 24h did not interfere on cell proliferation of human A375 and mouse K1735-M2 
melanoma cells [131]. However, on human C32 melanoma cells, A3AR activation elicited 
by micromolar concentrations of ADO or by nanomolar concentrations of the selective 
A3AR agonist Cl-IB-MECA induced cell proliferation. These findings suggest that 
activation of AR subtypes on melanoma cells is dependent on species and gender. In fact, 
C32 and A375 cells were collected from male and female, respectively, and different 
melanoma metastatic patterns were found on male and female patients [133]. The 
aforementioned results highlight the fact that caution should be taken in data 
extrapolation from mice to humans, and generalization of AR activation in human disease 
should be avoided. Nevertheless, these findings suggest that high expression of A3AR is 
not essential to obtain effects. In fact, it seems that although being poorly expressed, it is 
the only receptor subtype that mediates ADO effects on human C32 melanoma cells. 
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 On the other hand, Cl-IB-MECA at micromolar concentrations caused severe 
cytotoxicity on C32 cells, through A3AR-independent mechanisms [131,134]. This data is 
in accordance with the fact that Cl-IB-MECA inhibits cell proliferation of human thyroid 
cancer cells without A3AR activation [119]. Several possibilities could explain this effect, 
namely, loss of A3AR selectivity and/or A3AR desensitization [135]. Other possibilities 
include i) high concentrations of Cl-IB-MECA can bind to a yet unidentified membrane 
receptor and trigger downstream signalling or ii) Cl-IB-MECA can be transported into the 
cell via a NT, and once inside the cell signal through direct interaction with intracellular 
targets. However, the cytotoxic effect of Cl-IB-MECA in C32 cells was not prevented by the 
NT inhibitor NBTI (10 μM) [131,134], discarding the possibility that Cl-IB-MECA enters 
the cell by a NT-dependent mechanism, in our model. Nevertheless, one cannot discard 
the last possibility since Cl-IB-MECA can enter the cell through a NT-independent 
mechanism. 
 Evidence suggests that an increase in ADA activity can cause a reduction in the 
extracellular levels of ADO and, therefore, reduce tumour promotion [105]. The 
hypothesis that degradation of ADO would prevent melanoma cells proliferation was 
tested, since ADO induced proliferative effects on C32 melanoma cells [131]. The effects of 
ADO and its degradation (addition of ADA) were further studied, with the associated 
mechanisms being clarified. One major and surprising finding was that INO caused C32 
cell proliferation more pronouncedly than ADO itself, those effects being mediated by 
A3AR activation [136]. Moreover, reduction of cell proliferation by AOPCP (a ecto-5’NTase 
inhibitor, 100 μM) was demonstrated, suggesting that increased levels of AMP, in contrast 
to ADO, have an inhibitory effect on C32 cell proliferation [136]. Similar results obtained 
with AOPCP were reported in glioma [137] and breast [138] cancer cells. These findings 
highlight the complexity of the effects of ADO metabolism, suggesting that ADO 
degradation, through addition of ADA, is not a successful approach in preventing cell 
proliferation in this model. Indeed, this strategy may even worsen the clinical condition, 
since not only ADO, but also INO increases melanoma cell proliferation. Studies reporting 
increased levels of ADA in serum of patients with bladder [106], breast [139] and lung 
[140] cancer could be linked to our finding, suggesting a relevant role of the metabolic 
product of ADO in cancer. Attempts were also made in order to clarify the intracellular 
mechanisms by which INO mediates cell proliferation. Constitutive activation of PLC-
PKC-MEK1/2-ERK1/2 and PI3K pathways was found in C32 melanoma cells and INO 
showed to increase cell proliferation through further increments of these pathways [136]. 
Moreover, we provide proof that A3AR-MEK1/2-ERK1/2 activation is the major pathway 
responsible for the C32 proliferative effects elicited by INO. This finding is in agreement 
with the observation that normal melanocytes do not have detectable ERK activity, 
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requiring growth factors secreted by keratinocytes to survive, whereas melanoma cell lines 
have enhanced ERK activity due, in part, to autocrine factors stimulation [46]. Taking this 
into consideration, we propose INO as a stimulation autocrine factor for C32 melanoma 
cells. Moreover, although the MAPK pathway is primordial for cell proliferation, PI3K 
pathway is also essential, suggesting that both pathways may be possible targets for future 
melanoma anticancer therapy. These findings are in agreement with the fact that Ras-Raf-
MEK-ERK and PI3K-AKT signalling pathways being constitutively activated in melanoma 
exerting several key functions in melanoma development and progression [39]. Therefore, 
these pathways may represent promising therapeutic targets for the effective treatment of 
metastatic melanoma. 
 In view of the fact that micromolar concentrations of Cl-IB-MECA caused 
cytotoxicity in C32 cells [131], the following aim was to understand the intracellular 
mechanisms elicited by this synthetic nucleoside on melanoma cells. Moreover, attempts 
were made to explore the potential cytotoxic synergistic effects of the combination of Cl-
IB-MECA with a chemotherapeutic agent presently used in therapeutics, PXT. 
Combinations of cytotoxic agents may yield a slightly higher survival rate than 
monotherapies already in use for metastatic melanoma (reviewed in [66]). However, these 
combinations have been associated with higher toxicities [141]. In addition, melanoma 
usually relapses because most patients develop resistance to chemotherapeutics, namely 
to PXT [142]. The findings in this thesis demonstrate, for the first time, that the 
cytotoxicity induced by PXT is potentiated by the simultaneous use of Cl-IB-MECA (10, 
20, and 50 µM), at clinically relevant concentrations, in human C32 melanoma cells [143]. 
PXT concentrations used in this study (10-50 ng/ml) are much lower than those already 
tested in human bone marrow cells without collateral toxicity [144] and much higher than 
concentrations found in plasma of PXT-treated cancer patients [145]. A3AR agonists reveal 
differential effects on normal and malignant cells, without inhibiting normal cell growth 
[107] and Cl-IB-MECA is currently being tested in hepatocellular carcinoma patients and 
considered safe and well-tolerated [122]. Our proposed therapeutic combination seems to 
act synergistically in causing apoptosis in C32 cells, through enhancement of caspase 9, 8 
and 3 activities, although lower concentrations of Cl-IB-MECA (10 and 20 µM) alone did 
not lead to caspases activation [143]. These findings proved to be very important as even 
concentrations for which Cl-IB-MECA has no effect, when this compound was combined 
with the chemotherapeutic agent PXT, the cytotoxic effects were enhanced. However, the 
cytotoxicity found for the combination of Cl-IB-MECA (10, 20, and 50 µM) and PXT (10 
ng/mL) does not involve A3AR activation. Micromolar concentrations of Cl-IB-MECA (5-
80 μM) were also found to inhibit human thyroid carcinoma cell proliferation by a 
mechanism independent of the classical A3AR activation [119]. In fact, when the non 
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selective AR antagonist (CGS 15943, 100 nM) was combined with Cl-IB-MECA and PTX, 
cytotoxicity was even more pronounced, suggesting that blocking AR probably prevents 
the binding of endogenous ADO and/or its metabolic product INO, which could be 
involved in C32 cell survival. The putative protective role of these molecules is in 
agreement with previous findings that showed the ability of ADO and/or INO to enhance 
proliferation of human C32 melanoma cells [131,136]. 
 The combination of Cl-IB-MECA and PXT revealed a good therapeutic strategy 
(cytotoxicity) on metastatic melanoma treatment by induction of caspase-dependent 
apoptosis on human C32 melanoma cells. However, other mechanisms of cell death are 
definitively involved since the caspase inhibitor (Ac-DEVD-CHO, 50 μM) only prevented 
approximately 10% of the cytotoxic effects [143]. It is well accepted that the limited 
success of most current chemotherapeutic agents used in metastatic melanoma is, at least 
in part, related to cancer cells ability in escaping apoptosis, acquiring drug resistance [40]. 
Recently, another type of cell death, autophagy, has become an alternative approach to 
anticancer therapy, as pro-autophagic drugs seem to overcome drug resistance [146]. 
 Efforts were made in order to elucidate the other mechanisms of cell death elicited 
by the cytotoxic combination of Cl-IB-MECA and PXT, namely the possible involvement of 
autophagy. Moreover, to increase knowledge on the potential use of this anticancer 
therapeutic strategy, this combination was also tested in another melanoma cellular model 
besides C32 cells. Importantly, Cl-IB-MECA in combination with PXT not only causes 
apoptosis but also induces autophagy, causing cell death on human C32 and A375 
melanoma cells [147]. Activation of both apoptosis and autophagy has also been reported 
to occur in other human melanoma cells treated with a binuclear palladacycle complex 
[148]. While autophagy represents the main cell death mechanism of the drug 
combination for C32 cells, in A375 cells apoptosis and autophagy contribute equally to cell 
death [147]. This discrepancy between C32 and A375 cells concerning their susceptibility 
to the drug combination in study could be, in part, justified by the gender of each cell line 
donor, since different metastatic patterns were found on gender of patients with 
metastatic melanoma and C32 and A375 were collected from male and female donors, 
respectively [133]. This fact raises again the importance that generalization on gender 
human melanoma disease should be avoided as the progression of this disease is different 
in men and women. Therefore, individualized therapies would represent more efficient 
strategies for melanoma. 
 Despite mechanisms of autophagy regulation are not yet completely understood, 
evidence has shown that mTOR (a member of PI3K family) is involved in cell proliferation 
and plays a major role in preventing autophagy activation [149]. Results obtained with the 
combination of Cl-IB-MECA and PXT showed that levels of mTOR were decreased in C32 
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and A375 cells, as revealed by immunocytochemistry. Thus, it is conceivable that this 
combination inhibits the PI3K pathway, which was found to be constitutively activated in 
C32 cells [136]. The downregulation of mTOR and autophagy activation was found to be 
similar to that elicited by the PI3K inhibitor (LY294002, 50μM) [147]. In fact, autophagy 
has been reported to be regulated by suppression of mTOR expression [150]. 
 At this point the PXT mechanisms for cell death are poorly understood [151] and 
apoptosis was found to be more related to PXT whereas Cl-IB-MECA was with autophagy. 
Strong disruption of microtubule networks and induction of micro- and multinucleation, 
hallmarks of mitotic catastrophe, were observed to occur for PXT and for the combination 
of Cl-IB-MECA with PXT [147]. Moreover, induction of mitotic catastrophe was found to 
be both caspase-dependent and independent. Although caspase-dependent mitotic 
catastrophe is being suggested as a special case of apoptosis [152], mitotic catastrophe 
through mechanisms dependent and/or independent of caspase activation has been also 
reported [153], corroborating our findings [147]. Overall, these findings provide appealing 
mechanisms concerning melanoma chemotherapy, as induction of autophagy in 
melanoma cells that are also undergoing apoptosis, drives more cells to die. Therefore, 
this therapeutic strategy will potentially improve the effectiveness of PXT through 
activation of other forms of melanoma cell death. 
 It is well accepted that cellular proliferation is fundamental for melanoma 
metastasis [154]. The development of metastasis starts with cell migration from the 
primary tumour, followed by re-adhesion and tissue invasion, with complex interactions 
between tumour cells and their environment [155]. Based on the variety of cellular 
mechanisms involved in metastatic progression, attempts were made in order to find new 
effective drugs that might inhibit tumour cell proliferation, cell migration and/or invasion, 
and also drugs with anti-angiogenic properties. We had previously demonstrated that INO 
dramatically increases melanoma cell proliferation [136] and the combination of Cl-IB-
MECA with PXT revealed to be very efficient in the induction of melanoma cell death 
[143,147]. As such, the metastatic potential of human C32 and A375 melanoma cells was 
characterized. Afterwards, the role of INO on the promotion of the metastatic mechanisms 
and ability of the combination of Cl-IB-MECA with PXT in counteracting these effects 
were also investigated [156]. Our findings were the first demonstration that the 
combination of Cl-IB-MECA with PXT, is very efficient in preventing the metastatic 
process, stimulated by INO, on human C32 and A375 melanoma cells by (i) inhibiting cell 
proliferation; (ii) stopping cell migration; (iii) preventing cell adhesion; (iv) blocking cell 
invasion through the reduction of ERK1/2 levels; (v) diminishing colony formation ability; 
and (vi) reducing angiogenesis. In fact, although INO is considered a weaker but selective 
A3AR agonist [157], it works as an aggressiveness agent for these melanoma cells [156]. 
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Moreover, the effects enhanced by INO are A3AR-dependent, with the exception of the 
pro-angiogenic effect which is A3AR-independent. Nevertheless, the combination of Cl-IB-
MECA with PXT was able to abolish all of them, although with dissimilar importance on 
the two melanoma cell lines. A surprising finding was the fact that Cl-IB-MECA alone is 
able to block the metastatic processes enhanced by INO. Although micromolar 
concentrations of Cl-IB-MECA caused melanoma C32 cell cytotoxicity through AR-
independent mechanisms [134,143], it is conceivable that Cl-IB-MECA may prevent effects 
of INO involved in melanoma progression, through interaction with A3AR. These results 
are in agreement with works that describe Cl-IB-MECA (at micromolar concentrations) as 
a silent A3AR antagonist in the presence of micromolar concentrations of INO [158]. 
However, it is well established that A3AR agonists lose their selectivity at high 
concentrations [159], which suggest that Cl-IB-MECA could also mediate its effects by 
interaction with other AR subtypes, in these melanoma cellular models. To the best of our 
knowledge, it is the first time that Cl-IB-MECA is reported to cause anti-migration, anti-
adhesion, and anti-invasion effects on human melanoma cells, and this can, at least in 
part, explain the positive results of this compound in clinical assays [122]. Overall, the 
combination of Cl-IB-MECA with PXT revealed to be very efficient in stopping metastatic 
progression, as mechanisms not affected by PXT were impaired upon Cl-IB-MECA 
addition, thus overcoming the possible PXT chemotherapeutic resistance. 
 
 
2. FINAL CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 The ability of melanoma to metastasize results in early and general spread, causing 
very high mortality rates [1]. Resistance to chemotherapy and radiotherapy [66] is the 
main reason for patients with metastatic melanoma to have an overall survival rate of less 
than two years [1]. Chemotherapeutic drugs including alkylating agents (dacarbazine), 
platinum analogues (cisplatin, carboplatin) and anti-microbular agents (PXT) have been 
used, alone or in combination, although without significant survival rate improvement 
[66]. The lack of effective pharmacological approaches could be, at least in part, due to an 
incomplete understanding of the pathophysiological mechanisms involved in melanoma 
cells proliferation and, ultimately, tumour progression. 
 In this thesis, Cl-IB-MECA with PXT emerges as a promising cytotoxic 
combination for metastatic melanoma, acting through the induction of multiple 
mechanisms of cell death and blockade of several pathways involved in the metastatic 
potential of melanoma. This therapeutic strategy seems to overcome melanoma 
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multiresistance to chemotherapy and to stop, or delay, its progression, therefore, 
potentially improving metastatic melanoma treatment (Figure 8). 
 
Melanoma
cells
Apoptosis
Mitotic catastrophe
Autophagy
Caspase 9
Caspase 8
Caspase 3
mTOR
A3AR
Cl-IB-MECA
+
PXT
INOSINE
Proliferation  (PLC-PKC-MEK1/2-ERK1/2 and PI3K)
Migration
Adhesion
Invasion
Colony formation
Microvessel
sprouting
 
 
Figure 8. Postulated mechanisms for the cellular signalling pathways altered by the combination of Cl-IB-
MECA and PXT. This combination induces multiple mechanisms of cell death (apoptosis with the involvement 
of mitotic catastrophe, and mTOR-dependent autophagy) and blocks several processes involved in melanoma 
progression, enhanced by inosine, namely, proliferation, migration, adhesion, invasion, colony formation 
(A3AR activation), and microvessel sprouting (independent of A3AR activation) as an angiogenesis indicator. 
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Although the strategy of counteracting the in vitro growth and progression of 
melanoma through the combination of Cl-IB-MECA and PXT seems to represent a 
promising therapeutic approach, the effects of this combination on normal melanocytes 
and co-cultures of melanoma cells with fibroblasts and/or keratinocytes, would be 
important to evaluate, as collateral toxicity represents enormous limitations in the 
development of novel therapies. Moreover, future studies using animal models are also 
needed to better understand the potential of this combination in anticancer therapy 
towards melanoma before clinical trials can be performed. 
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